JPS6153324B2 - - Google Patents
Info
- Publication number
- JPS6153324B2 JPS6153324B2 JP52132965A JP13296577A JPS6153324B2 JP S6153324 B2 JPS6153324 B2 JP S6153324B2 JP 52132965 A JP52132965 A JP 52132965A JP 13296577 A JP13296577 A JP 13296577A JP S6153324 B2 JPS6153324 B2 JP S6153324B2
- Authority
- JP
- Japan
- Prior art keywords
- urea
- compound
- group
- propyl
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000949 anxiolytic effect Effects 0.000 claims description 18
- 150000003672 ureas Chemical class 0.000 claims description 14
- 239000002249 anxiolytic agent Substances 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- UPOPAKZLMRJBED-UHFFFAOYSA-N 4-propylheptan-4-ylurea Chemical compound CCCC(CCC)(CCC)NC(N)=O UPOPAKZLMRJBED-UHFFFAOYSA-N 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- XGEGHDBEHXKFPX-NJFSPNSNSA-N methylurea Chemical group [14CH3]NC(N)=O XGEGHDBEHXKFPX-NJFSPNSNSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003091 serenic agent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 description 75
- 241000699670 Mus sp. Species 0.000 description 43
- 238000012360 testing method Methods 0.000 description 33
- 229940126062 Compound A Drugs 0.000 description 18
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 18
- 230000001624 sedative effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000000144 pharmacologic effect Effects 0.000 description 15
- 229960003529 diazepam Drugs 0.000 description 14
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000019901 Anxiety disease Diseases 0.000 description 11
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229960004815 meprobamate Drugs 0.000 description 11
- 230000016571 aggressive behavior Effects 0.000 description 10
- 230000036506 anxiety Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000002539 anti-aggressive effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 230000000147 hypnotic effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- -1 tri-substituted methylurea groups Chemical group 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000003137 locomotive effect Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- JLEHSYHLHLHPAL-UHFFFAOYSA-N tert-butylurea Chemical compound CC(C)(C)NC(N)=O JLEHSYHLHLHPAL-UHFFFAOYSA-N 0.000 description 5
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 4
- 229940005530 anxiolytics Drugs 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010825 rotarod performance test Methods 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 239000003204 tranquilizing agent Substances 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 3
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- CNWSQCLBDWYLAN-UHFFFAOYSA-N butylurea Chemical compound CCCCNC(N)=O CNWSQCLBDWYLAN-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229960005152 pentetrazol Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- SECNBELURGTCTL-UHFFFAOYSA-N 1-methyl-1,3,3-tripropylurea Chemical compound CCCN(C)C(=O)N(CCC)CCC SECNBELURGTCTL-UHFFFAOYSA-N 0.000 description 2
- DYOHADODBLZBFQ-UHFFFAOYSA-N 1-methyl-3-(4-propylheptan-4-yl)urea Chemical compound CCCC(CCC)(CCC)NC(=O)NC DYOHADODBLZBFQ-UHFFFAOYSA-N 0.000 description 2
- NHWATURALCIMTO-UHFFFAOYSA-N 1-prop-2-enyl-3-(4-propylheptan-4-yl)urea Chemical compound CCCC(CCC)(CCC)NC(=O)NCC=C NHWATURALCIMTO-UHFFFAOYSA-N 0.000 description 2
- OVUWGANMOQIFHZ-UHFFFAOYSA-N 2-methylbutan-2-ylurea Chemical compound CCC(C)(C)NC(N)=O OVUWGANMOQIFHZ-UHFFFAOYSA-N 0.000 description 2
- CNZODTYLYDGSPX-UHFFFAOYSA-N 3-ethylpent-1-yn-3-ylurea Chemical compound CCC(CC)(C#C)NC(N)=O CNZODTYLYDGSPX-UHFFFAOYSA-N 0.000 description 2
- KTVHWABXSLMMCT-UHFFFAOYSA-N 3-ethylpentan-3-ylurea Chemical compound CCC(CC)(CC)NC(N)=O KTVHWABXSLMMCT-UHFFFAOYSA-N 0.000 description 2
- UQNMGFCOYWCTQG-UHFFFAOYSA-N 3-methylpentan-3-ylurea Chemical compound CCC(C)(CC)NC(N)=O UQNMGFCOYWCTQG-UHFFFAOYSA-N 0.000 description 2
- JPBUPPDXMPCBKV-UHFFFAOYSA-N 5-butylnonan-5-ylurea Chemical compound CCCCC(CCCC)(CCCC)NC(N)=O JPBUPPDXMPCBKV-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000003956 methylamines Chemical class 0.000 description 2
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical compound NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RMEFTJRBIGNUBG-UHFFFAOYSA-N (2-methyl-4-propylheptan-4-yl)urea Chemical compound CCCC(CCC)(CC(C)C)NC(N)=O RMEFTJRBIGNUBG-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UYXXCSAFQSKURR-UHFFFAOYSA-N 1,1-dimethyl-3-(4-propylheptan-4-yl)urea Chemical compound CCCC(CCC)(CCC)NC(=O)N(C)C UYXXCSAFQSKURR-UHFFFAOYSA-N 0.000 description 1
- YBBLOADPFWKNGS-UHFFFAOYSA-N 1,1-dimethylurea Chemical compound CN(C)C(N)=O YBBLOADPFWKNGS-UHFFFAOYSA-N 0.000 description 1
- YGTWGHMZFKZTCZ-UHFFFAOYSA-N 1-(4-propylheptan-4-yl)-3-prop-2-ynylurea Chemical compound CCCC(CCC)(CCC)NC(=O)NCC#C YGTWGHMZFKZTCZ-UHFFFAOYSA-N 0.000 description 1
- HLNNDIVDMQMWRJ-UHFFFAOYSA-N 1-cyclohexyl-3-(3-propylhexan-2-yl)urea Chemical group CCCC(CCC)C(C)NC(=O)NC1CCCCC1 HLNNDIVDMQMWRJ-UHFFFAOYSA-N 0.000 description 1
- FLZHTBKTUMOTSG-UHFFFAOYSA-N 1-methyl-3-(4-propylhept-1-en-4-yl)urea Chemical compound CCCC(CCC)(CC=C)NC(=O)NC FLZHTBKTUMOTSG-UHFFFAOYSA-N 0.000 description 1
- FQNZVZBSDBFSKF-UHFFFAOYSA-N 2,4,4-trimethylhexan-2-ylurea Chemical compound CCC(C)(C)CC(C)(C)NC(N)=O FQNZVZBSDBFSKF-UHFFFAOYSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- DWSYINQJVVITME-UHFFFAOYSA-N 2-methylbut-3-yn-2-ylurea Chemical compound C#CC(C)(C)NC(N)=O DWSYINQJVVITME-UHFFFAOYSA-N 0.000 description 1
- GYMUVPMHCVZTPH-UHFFFAOYSA-N 2-methylhexan-2-ylurea Chemical compound CCCCC(C)(C)NC(N)=O GYMUVPMHCVZTPH-UHFFFAOYSA-N 0.000 description 1
- YNTARSQYHLHBGV-UHFFFAOYSA-N 2-methylpentan-2-ylurea Chemical compound CCCC(C)(C)NC(N)=O YNTARSQYHLHBGV-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XJQKHXXRLQIHMS-UHFFFAOYSA-N 3-butyl-1,1-dimethylurea Chemical compound CCCCNC(=O)N(C)C XJQKHXXRLQIHMS-UHFFFAOYSA-N 0.000 description 1
- QQUXUBJSSVXXJN-UHFFFAOYSA-N 3-methylheptan-3-ylurea Chemical compound CCCCC(C)(CC)NC(N)=O QQUXUBJSSVXXJN-UHFFFAOYSA-N 0.000 description 1
- IYXGRCFDWHJJIZ-UHFFFAOYSA-N 3-methylhex-1-yn-3-ylurea Chemical compound CCCC(C)(C#C)NC(N)=O IYXGRCFDWHJJIZ-UHFFFAOYSA-N 0.000 description 1
- ORNKDYDBJSKYCS-UHFFFAOYSA-N 3-methylpent-1-yn-3-ylurea Chemical compound CCC(C)(C#C)NC(N)=O ORNKDYDBJSKYCS-UHFFFAOYSA-N 0.000 description 1
- GXJWKOQDAJVDKL-UHFFFAOYSA-N 4-isocyanato-4-propylheptane Chemical compound CCCC(CCC)(CCC)N=C=O GXJWKOQDAJVDKL-UHFFFAOYSA-N 0.000 description 1
- MNRHWBIDXLFCMS-UHFFFAOYSA-N 4-propan-2-ylheptan-4-ylurea Chemical compound CCCC(CCC)(NC(N)=O)C(C)C MNRHWBIDXLFCMS-UHFFFAOYSA-N 0.000 description 1
- NQTPBZYCRLNRGR-UHFFFAOYSA-N 4-propylhept-1-en-4-ylurea Chemical compound CCCC(CCC)(CC=C)NC(N)=O NQTPBZYCRLNRGR-UHFFFAOYSA-N 0.000 description 1
- XOAKIPLOYQKFOQ-UHFFFAOYSA-N 4-propylhept-2-yn-4-ylurea Chemical compound CCCC(CCC)(NC(N)=O)C#CC XOAKIPLOYQKFOQ-UHFFFAOYSA-N 0.000 description 1
- OICNXKVUQLMSFO-UHFFFAOYSA-N 4-propyloct-5-yn-4-ylurea Chemical compound CCCC(CCC)(NC(N)=O)C#CCC OICNXKVUQLMSFO-UHFFFAOYSA-N 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ANTGQBPGYZDWAW-UHFFFAOYSA-N azane;1,4-dioxane Chemical compound N.C1COCCO1 ANTGQBPGYZDWAW-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000003086 effect on acetylcholine Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical class NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012345 traction test Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯ãå°¿çŽ èªå°äœãå«ãè¬çåã³ç£å»åŠçš
çµæç©ã«é¢ããã æ¬çºæã®è¬ç掻æ§ã®ããå°¿çŽ èªå°äœã¯ã次ã®äž
è¬åŒ ãåŒäžR1ãR2åã³R3ã¯åäžåã¯çžç°ã€ãŠå€«ã ççŽ
æ°ïŒãïŒã®çŽéç¶åã¯åæç¶ã®ã¢ã«ãã«åºåã¯ã¢
ã«ããã«åºåã¯ïŒâããããã«åºããR4åã³R5
ã¯åäžåã¯çžç°ã€ãŠå€«ã æ°ŽçŽ åååã¯ççŽ æ°ïŒã
ïŒã®çŽéç¶åã¯åæç¶ã®ã¢ã«ãã«åºãã¢ã«ã±ãã«
åºåã¯ã¢ã«ããã«åºã瀺ããäœããR1ãR2åã³
R3ã«é¢ãã (a) ãã®ãã¡å¯äžã€ã®åºã®ã¿ããã¡ãã«å°¿çŽ åºã«
é¢ããŠÎ±ãβäœã«äžé£œåçµåãæããã¢ã«ãã
ã«åºã瀺ãããã®å Žåä»ã®ïŒã€ã®åºã¯å€«ã ã¢ã«
ãã«åºã瀺ããã®ãšããæŽã« (b) ãããåºã®ççŽ æ°ã®ç·åã¯ãïŒæªæºãšãªããª
ããã®ãšãããã ã§è¡šããããã äžè¬åŒïŒïŒã®ååç©ã®ãã¡ã«ã¯ãäžæŽççŽ ã
æãããã®ãå å«ãããŠãããæ¯ããååç©ã«é¢
ããŠã¯ããã®ã©ã»ãæ··åç©åã³çžåœããå åŠç°æ§
äœãæ¬çºæã«å å«ãããã åŸèšè©³è¿°ããæ§ã«ãæ¬çºæã®å°¿çŽ èªå°äœã¯ãé¡
èãªè¬çç¹æ§ãæããå»åŠåã³ç£å»åŠäžã®æ²»çç¹
ã«ç çäžå®åã³æ»ææ§ã®æ²»çã«æçšã§ããã åŸã€ãŠæ¬çºæã¯ãç çäžå®åã³æ»ææ§ã®æ²»çã«
䜿çšããè¬çåã¯ç£å»åŠççµæç©ãæäŸããããš
ããã®ç®çã®ïŒã€ãšããŠå å«ããã該çµæç©ã¯ã
å¿ é æå¹æåãšããŠäžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã®
å°ãªããšãäžçš®ãè¬çæ äœåã¯è³Šåœ¢å€ãšå ±ã«å«æ
ããã æ¬çºæã®ä»ã®ç®çã¯ãé©åœãªè¬çæ äœåã¯è³Šåœ¢
å€ãšå ±ã«äžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã®å°ãªããšã
ïŒçš®ãå«ããç çäžå®åã³æ»ææ§ã®æ²»ççšã®è¬ç
åã¯ç£å»åŠççµæç©ã®è£œé æ³ãæäŸããããšã§ã
ãã æŽã«æ¬çºæã®ä»ã®ç®çã¯ãæ²»çãå¿ èŠãšããŠã
ãæ£è ã«äžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã®å°ãªããšã
ïŒçš®ãæå¹éæäžããŠè©²æ£è ã®ç çäžå®åã³æ»æ
æ§ãæ²»çããæ¹æ³ãæäŸããããšã§ããã äœé60Kgã®äººã«æäžããå Žåãäžæ¥åœããæå¹
æå400ã1200mgã®æäžéã§æäžããã®ã奜ãŸã
ãã äžè¬åŒïŒïŒã®ååç©ã®äžã«ã¯ãæ¢ã«å è¡ç¹èš±
ãåè¡ç©ã«èšèŒãããŠå ¬ç¥ãšãªã€ããã®ãå«ãŸã
ãŠãããäŸãã°ãïŒâïŒïŒã»ïŒâãžâïœâããã«
âïœâãã³ãã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãžã¡ãã«
âïœâããã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãžã¡ãã«â
ïœâãããã«ïŒâå°¿çŽ ãïŒâïŒïŒâã¡ãã«âïŒâãš
ãã«âïœâãããã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãžã¡
ãã«âïœâãã³ãã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒã»ïŒã»
ïŒâããã©ã¡ãã«âïœâããã«ïŒâå°¿çŽ ãïŒâ
ïŒïŒã»ïŒã»ïŒã»ïŒâããã©ã¡ãã«âïœâãã³ã
ã«ïŒâå°¿çŽ åã³ïŒâïŒïŒã»ïŒâãžã¡ãã«âãšãã«ïŒ
âå°¿çŽ ã¯ç±³åœç¹èš±ç¬¬3847981å·ã«èšèŒãããŠã
ããããããªããããã®ç¹èš±ã«ã¯äžèšèªå°äœã®è¬
ç掻æ§ã«é¢ããŠã¯äœãèšèŒãããŠããªãã ã±ãã«ã« ã¢ãã¹ãã©ã¯ã80ã74ã36814jã«
ã¯ãïŒâïŒïŒâããããã«ïŒâå°¿çŽ ã®èªå°äœæ°çš®å³
ã¡ïŒâïŒïŒã»ïŒâãžã¡ãã«âïŒâããããã«ïŒâå°¿
çŽ ãïŒâïŒïŒâã¡ãã«âïŒâãšãã«âïŒâããã
ãã«ïŒâå°¿çŽ åã³ïŒâïŒïŒâã¡ãã«âïŒâïœâãã
ãã«âïŒâããããã«ïŒâå°¿çŽ ãèšèŒãããŠãã
ãããã®è¬çç¹æ§ã«é¢ããŠã¯äœãèšèŒããªãã åæ§ã«ãç±³åœç¹èš±ç¬¬3852473å·ã«ã¯ãïŒâïŒïŒã»
ïŒâãžã¡ãã«âãšãã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãž
ã¡ãã«âãããã«ïŒâå°¿çŽ åã³ïŒâïŒïŒâã¡ãã«â
ïŒâãšãã«âãããã«ïŒâå°¿çŽ ãèšèŒãããŠã
ãã該米åœç¹èš±ã«ã¯ãåèšäžè¬åŒïŒïŒã§è¡šãã
ããäžèšä»¥å€ã®èªå°äœãåç©äŸãã°çã®å€é£ãèª
çºããŠæé·ãä¿é²ãããè¬å€ãšãªãåŸãããšãè¿°
ã¹ãããŠãããããããªããæ¯ããç¹æ§ã¯äžèšïŒ
çš®ã®ååç©ã«ã€ããŠã®ã¿ç«èšŒãããŠããã ãã§ã
ããåŸã€ãŠãã®ç±³åœç¹èš±ã«å å«ãããèªå°äœå šãŠ
ãæ¯ããç¹æ§ãæããŠãããšã¯çµè«ã§ããªãã äžæ¹ãäžè¬åŒïŒïŒã®ååç©ã®äžã«ã¯ãå è¡æ
è¡ãšããŠåŒçšããåã¯èšèŒãããŠããããåŸã€ãŠ
æ°èŠååç©ã§ãããã®ãããã åŸã€ãŠæ¬çºæã¯ãäžè¬åŒïŒïŒã§è¡šããããæ°
èŠãªå°¿çŽ èªå°äœå³ã¡R1åã³R3ãåäžã§å€«ã ãšã
ã«åºåã¯ïœâãããã«åºããR2ããšãã«åºãïœ
âãããã«åºãã€ãœãããã«åºãïŒâã¡ãã«âã
ããã«åºãã¢ãªã«åºããšããã«åºãïŒâãããã
ã«åºåã¯ïŒâãããã«åºããR4ãæ°ŽçŽ ååãã¡
ãã«åºãã¢ãªã«åºåã¯ãããã«ã®ã«åºããR5ã
æ°ŽçŽ åååã¯ã¡ãã«åºã瀺ããã®ãæäŸããããš
ããã®ç®çã®ïŒã€ãšããŠå å«ããã ãã®ãã¡å¥œé©ãªååç©ã¯ãR1åã³R3ãåäžã§
ãšãã«åºåã¯ïœâãããã«åºããR2ããšãã«ã
ïœâãããã«ãã¢ãªã«ããšããã«ãïŒâãããã
ã«åã¯ïŒâãããã«ã®ååºããR4åã³R5ã倫ã
æ°ŽçŽ ååã瀺ããã®ã§ããã åã次ã®äžè¬åŒã§è¡šããããååç©ãæ¬çºæã®
奜é©ãªååç©ã§ãããå³ã¡ ãåŒäžR2ã¯ïœâãããã«ãã¢ãªã«ãïŒâãããã
ã«åã¯ïŒâãããã«ã®ååºã瀺ããã ã§è¡šããããååç©ã§ããã äžè¬åŒïŒïŒã®ååç©ã¯ãé©åœãªæº¶åªäŸãã°
æ°Žããšãã«ãšãŒãã«ãããã¿ã³ããã³ãŒã³ããã«
ãšã³çäžã§äžè¬åŒ ãåŒäžR1ãR2åã³R3ã¯äžè¬åŒïŒïŒã«ããããã
ããšåãã§ããã ã§è¡šããããã€ãœã·ã¢ããŒããšäžè¬åŒ R4âNHâR5 ïŒïŒ ãåŒäžR4åã³R5ã¯äžè¬åŒïŒïŒã«ãããããããš
åãã§ããã ã§è¡šããããååç©ãšãåå¿ãããããšã«ããåŸ
ãããããã®å Žåäžè¬åŒïŒïŒã®ã€ãœã·ã¢ããŒã
ããäžè¬åŒïŒïŒã®ååç©ãé©åœãªæº¶åªäžã«æº¶è§£
ããã溶液äžã«å ããã®ã奜ãŸãããåå¿æž©åºŠ
ã¯ã宀枩ä¹è³çšãã溶åªã®æ²žç¹ãŸã§ã®æž©åºŠã䜿çš
ã§ãããåãäžè¬åŒïŒïŒã®ååç©ãšããŠR4å
ã³R5ãæ°ŽçŽ ååã瀺ããã®å³ã¡ã¢ã³ã¢ãã¢ã䜿
çšããå Žåã«ã¯ãæ°Žåã¯ææ©æº¶åªäŸãã°ãžãªããµ
ã³çã«æº¶è§£ãããç¶æ ã§å ããã ä»ã®æ¹æ³ã«äŸãã°ãR4åã³R5ã倫ã æ°ŽçŽ åå
ã§ããäžè¬åŒïŒïŒã®ååç©ã¯ãäžè¬åŒ ãåŒäžR1ãR2åã³R3ã¯äžè¬åŒïŒïŒã®å Žåãšåã
ã§ããã ã§è¡šããããã¡ãã«ã¢ãã³èªå°äœããããå°¿çŽ ãš
å ±ã«å ç±ããããšã«ããåŸãããã奜ãŸããã¯ã
åå¿ãæ°Žäžã§30ã70â奜ãŸããã¯çŽ50âã®æž©åºŠäž
ã«è¡ãªãã®ãããããã®æ¹æ³ã¯ãç¹ã«ããªâ眮æ
ã¡ãã«å°¿çŽ åºã«é¢ããŠÎ±ã»Î²âäœã«äžé£œåçµåã
æããæ¬çºæã®å°¿çŽ èªå°äœã補é ããã®ã«çšãã
ããã åæ§ã«äžè¬åŒïŒïŒã®ååäžR4ãççŽ æ°ïŒã
ïŒã®çŽéåã¯åæã®ã¢ã«ãã«åºãã¢ã«ã±ãã«åºå
ã¯ã¢ã«ããã«åºããR5ãæ°ŽçŽ ååã瀺ããã®
ã¯ã宀枩äžåã¯å ç±äžäŸãã°ãšãã«ãšãŒãã«çã®
é©åœãªæº¶åªäžã§äžè¬åŒïŒïŒã§è¡šããããã¡ãã«
ã¢ãã³èªå°äœãšäžè¬åŒ R4âïŒïŒ£ïŒïŒ¯ ïŒïŒ ãåŒäžR4ã¯äžèšã«åãã ã§è¡šããããã€ãœã·ã¢ããŒããšãåå¿ãããããš
ã«ããåŸããããåå¿æž©åºŠã¯äœ¿çšããåå¿è©Šè¬ã«
ããç°ãªããã宀枩ãã110âã®æž©åºŠã奜ãŸã
ããåãäžè¬åŒïŒïŒã®ã€ãœã·ã¢ããŒããé©åœãª
溶åªã«æº¶è§£ããã溶液äžã«äžè¬åŒïŒïŒã®ã¢ãã³
ãå ããã®ã奜ãŸããã äžè¬åŒïŒïŒåã³ïŒïŒã®ååç©ã®äžã«ã¯ãç±³
åœç¹èš±ç¬¬4026925å·ã«èšèŒãããŠãããã®ãã
ãããã®ä»ã®äžè¬åŒïŒïŒåã³ïŒïŒã®ååç©ã¯
該米åœç¹èš±ã«èšèŒã®æ¹æ³ã«ãã補é ããããšãã§
ããã äžæ¢ç¥çµç³»ã«é¢ããè¬çç¹æ§ãã詳ããã¯ç²Ÿç¥
å®å®ãäžå®é€å»ãçèæœç·©ãé®éãå¬ç åã³æç
æ£ã®åäœçšãæããå°¿çŽ èªå°äœã¯å ¬ç¥ã§ããã ãã®èªå°äœã®æçš®ã®ãã®äŸãã°ããšãã«ã¢ã»ã
ã«å°¿çŽ ãããã¢ãžãšãã«ã¢ã»ãã«å°¿çŽ ãαâãã
ã¢ã€ãœãã¬ãªã«å°¿çŽ çã¯æ¢ã«åžè²©ãããŠãããä»
ã®ãã®ã¯äŸãã°ç±³åœç¹èš±ç¬¬2999110å·åã³ç¬¬
3110728å·ãè±åœç¹èš±ç¬¬1056833å·ããã©ã³ã¹åœç¹
蚱第5431 ïŒå·åã³ãã€ãæ°äž»å ±ååœç¹èš±ç¬¬21573
å·çã®å è¡ç¹èš±åã¯å è¡åè¡ç©ã«èšèŒãããŠã
ãã äžèšç¹èš±ã«ãããŠç²Ÿç¥å®å®å€åã¯äžå®é€å»å€ãš
ããŠèšèŒãããŠããå°¿çŽ èªå°äœã¯ããã®ååäž
ã«ãå°¿çŽ åºãæ§æãããã®ä»¥å€ã®ãããååãæ
ããŠããããšã«ããç¹åŸŽä»ãããããå³ã¡ããã²
ã³ååãé žçŽ ååããç¹ã«ã«ã«ããã«åºåã¯ãã
ããã·ã«åºã®åœ¢ã§å«ãã§ããã æŽã«ãtertâããã«âå°¿çŽ ã¯ãArch.Int.
Pharmacodyn.219ã103â115ïŒ1976ïŒã«æçæ£ã
å¬ç åã³é®éã®åäœçšãæããè¬å€ãšããŠåã³ã
ã«ãããŒã«é žå¡©ã®å¬ç äœçšã®çžä¹äœçšå€
ïŒPotentiatorïŒãšããŠèšèŒãããŠãããåãïœâ
ããã«âå°¿çŽ ããArch.Int.Pharmaeodyn208ã
204â212ïŒ1974ïŒã«tertâããã«âå°¿çŽ ãšåæ§ãª
äœçšãæããããšãèšãããŠããã ããããªããä¹çåè¡ç©ã¯ãïœâããã«âå°¿çŽ
åã¯tertâããã«âå°¿çŽ ãäžå®é€å»
ïŒanxiolyticïŒåã¯ææ»æäœçšãæããããšã瀺å
ãããã®ã§ã¯ãªãã ïŒçš®ã®å°¿çŽ èªå°äœããChimie Therapeutigue
No.4ãpp.412ã418ã«èšãããŠããããã®ãã¡ã®
ïŒçš®ã¯ïŒâïŒïŒâã¡ãã«âïŒâãããã«âãã³ã
ã«ïŒâïŒâã·ã¯ãããã·ã«âå°¿çŽ ã§ããããã®æ
ç®ã¯ãäžèšïŒçš®ã®ååç©ã«é¢ããæ°çš®ã®è¬çè©Šéš
ã«ã€ããŠèšèŒãããã®ã§ãããããããªãããäž
å®é€å»æ§åã¯ææ»ææ§ã®éç¥å®å®äœçšã«ã€ããŠã¯
äœãè¿°ã¹ãããŠããªãã ãšãããé©ãã¹ãäºã«ãïŒâïŒïŒâã¡ãã«âïŒ
âãããã«âãã³ãã«ïŒâïŒâã·ã¯ãããã·ã«â
å°¿çŽ ãtertâããã«âå°¿çŽ åã³ïœâããã«âå°¿çŽ
ãšé¡äŒŒã®ååŠæ§é ãæããäžã€ãããååããª
ããåã«èèªæçåæ°ŽçŽ åºãæããããšãç¹åŸŽãš
ããäžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã¯ãæçšãªäžå®é€
å»åã³ææ»æäœçšãçºæ®ããããšãå€æããã ã¡ãã«å°¿çŽ ã®ããªãŒçœ®æèªå°äœã¯ãéç¥å®å®å€
åã¯äžå®é€å»å€ãšããŠæå¹ãªå°¿çŽ èªå°äœãéåžžæ
ãã眮æåºãïŒâäœã«æããŠããç¹ã§äžè¬åŒ
ïŒïŒã§è¡šããããèªå°äœãšé¡äŒŒããã«ãããã
ãããäžå®é€å»åã¯ææ»æäœçšã«é¢ããŠã¯äžæŽ»æ§
ã§ãããåã¯å®è³ªçã«æ¯ããäœçšãæããªããã
ã®ããšãèæ ®ãããšãäžèšç¥èŠã¯å®ã«äºæ³å€ã®ã
ãšã§ããã å ããŠãæ¬çºæååç©ã¯ãè¡ååã³éååã«åœ±
é¿ãäžããªãéã®æäžéã§äžå®é€å»äœçšãçºæ®ã
ãã®ã§ããããã®äºå®ã¯ãå è¡æè¡ç¹ã«ãã©ã³ã¹
å»è¬ç¹å¥ç¹èš±ç¬¬5341 ïŒå·ããã¯å šãäºæž¬ã§ããª
ãããšã§ãããäºå®ã該ãã©ã³ã¹å»è¬ç¹å¥ç¹èš±ã«
å å«ãããèªå°äœã¯ãé®éæäžéïŒsedative
dosesïŒã§äžå®é€å»äœçšãæãããšèšãããŠã
ãã æ¯ãããŠãé®éäœçšããäžå®é€å»äœçšãåé¢ã
åŸããšããæ¬çºæååç©ã«ããããããããå¹æ
ã¯ãäžèšãã©ã³ã¹å»è¬ç¹å¥ç¹èš±ã«å å«ãããåå
ç©åã³æãçš®ã®åžè²©ååç©äŸãã°ãžã¢ãŒãã
ïŒdiazepamïŒãã¡ãããã¡ãŒãïŒmeprobamateïŒ
çã«æ¯ã極ããŠåªããå©ç¹ãããã æãçšåºŠã®åŸç åã³æ³šæéäžåã®åªå€±ããä¹ç
粟ç¥å®å®å€ã®æ¬ ç¹ã§ããããšãç¥ããŠããããã®
çºã«ãç·»å¯ãªæ³šæåãèŠããè·æ¥ã«å°±ããŠãã人
ãèªåè»ã®é転æçãå€æ¥éé¢æ²»çããå ŽåïŒin
ambulatory therapyïŒã«ã¯æ éããèŠããã®ã§
ããã ããã«å¯Ÿããæ¬çºæååç©ã¯ãåŸæ¥ã®æ²»çæ³ã«
æ¯ãæçšãªå©ç¹ããããããå³ã¡ãæ¬çºæååç©
ã¯ãäžå®é€å»ã«æå¹ãªæäžéã«ãããŠé®éåã¯å¬
ç äœçšãå šãåãŒããªãã®ã§ãããåŸã€ãŠæ¬çºæ
ååç©ã䜿çšããå Žåã«ã¯ã泚æéäžåã«åœ±é¿ã
äžãããåŸã€ãŠåŸæ¥å ¬ç¥ã®äžå®é€å»å€ãçšããå Ž
åã«æ¹èµ·ããããæ²»çã®åŠšããšãªãæãçš®ã®çŠå¿
ãåé¿ããããšãã§ããã æ¬çºæååç©ã«ã¯ãæŽã«ã極ããŠæ¯æ§ãäœããš
ããç¹åŸŽãããããã®å©ç¹ã¯ç²Ÿç¥å»åŠã®åéã§ç¹
ã«éèŠæ§ãããããªããªãã°ããã®åéã«ãããŠ
ã¯éå°æäžã«ããèªæ®ºè¡åãæ¹èµ·ããããšããã°
ãã°ããããã§ããã æŽã«ãæ¬çºæååç©ã粟ç¥å®å®äœçšãçºæ®ãã
éæäžïŒtranguillising dosesïŒããå Žåãäžæ¢
åã¯æ«æ¢¢ã³ãªã³æå¶æ§äœçšã«åž°å ãã奜ãŸãããª
ãå¯äœçšäŸãã°å£å 也ç¥ãèŠèŠèª¿ç¯ïŒoptical
accommodationïŒã®å°é£ãçºæ±ãé »èçãäœãæ¹
èµ·ããªãã ãã®èŠ³ç¹ãããæ¬çºæååç©ã¯æçšã§ãå»åž«ã¯
æã®ãŸãŸã«æ²»çãè¡ãªãããšãã§ãããå¿ èŠãšã
ãã°ãäŸãã°æ£è ã®ç¶æ å€åãç¿æ £æ§çäœããã®
çç±ã§äœ¿çšã§ããªããã®ãšãªã€ãè¬å€ã«ä»£ããŠæ¬
çºæååç©ãçšããŠæ²»çãè¡ãªãåŸãã æ¬çºæååç©äžãæãé¡èãªäžå®é€å»åã³ææ»
æäœçšã瀺ããã®ã¯ãïŒâïŒïŒã»ïŒâãžâïœâã
ããã«âïœâããã«ïŒâå°¿çŽ å³ã¡ããªâïœâãã
ãã«ã¡ãã«å°¿çŽ ã§ããã æ¬çºæã®ãã®å¥œé©ãªååç©ã«ã€ããŠæŽã«è¬çè©Š
éšãè¡ã€ãæãéé®éæäžéã§ã¯ãã«ãããŒã«é ž
å¡©ã®å¬ç äœçšäžŠã³ã«ã¡ãããã¡ã€ãåã³ãžã¢ãŒã
ã çã®ç²Ÿç¥å®å®å€ã®é®éäœçšã«å¯Ÿãçžä¹äœçšã瀺
ããæŽã«ã該ååç©ã¯ãšã¿ããŒã«ã®äœçšã«å¯ŸããŠ
ã¯ãããããçžä¹äœçšã瀺ããªãã€ãã æŽã«æ¬çºæã®å¥œé©ååç©ã¯ãå¿èµè管系åã¯åŒ
åžåšç³»ã«å¯ŸããŠåœ±é¿ãåãŒããªããäºå®ãæ¬çºæ
ã®äžèšå¥œé©ååç©ã¯ã麻é ããã©ããã«100mg/Kg
åã³200mg/Kgè ¹è å æäžããå Žåã該ã©ããã®å š
身系åèè¡å§ãå¿ææ°åã³åŒåžæ°ãå€åãããª
ãã åæ§ã«ãæ¬çºæã®äžèšå¥œé©ååç©ãã©ããã«
100mg/Kgæäžããå Žåãã¢ã»ãã«ã³ãªã³ã«ããèª
çºãããäœè¡å§çåã³åŸèã«å¯Ÿãäœã®åœ±é¿ãäžã
ãªããåéå³ã¡200mg/Kgãè ¹è å 泚å°ããå Žåã«
ãããšããããªã³ã«ããæ¹èµ·ãããαâã¢ãã¬ã
ãªã³äœåæ§äœçšåã¯Î²âã¢ãã¬ããªã³äœåæ§äœçš
ãå€åãããªããæ¬çºæã®å¥œé©ååç©ã¯ä¹ç奜ãŸ
ãããªãå¯äœçšãæããªãçºãå¿èé害åã³åè
è¡å§ã®é害ãæ¹èµ·ããªãã æ¬çºæååç©ã®æ¯æ§ã調ã¹ãçºåæ¬çºæååç©
ã粟ç¥å®å®å€ãšããŠæçšãªä»ã®ç¹æ§ãæãããåŠ
ãã«ã€ããŠè¬çè©Šéšãè¡ã€ãã äŸãšããŠäžèšååç©ã«ã€ããŠåŸãããè©Šéšçµæ
ã次ã«è¿°ã¹ãã ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
å°¿çŽ ïŒååç©ïŒ¡ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâãã³ãã
ã«ïŒâå°¿çŽ ïŒååç©ïŒ¢ïŒ ïŒâïŒïŒã»ïŒâãžãšãã«âïŒâããããã«ïŒâå°¿çŽ
ïŒååç©ïŒ£ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâããã
ã«ïŒâå°¿çŽ ïŒååç©ïŒ€ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâããã
ã«ïŒâå°¿çŽ ïŒååç©ïŒ¥ïŒ ïŒâïŒïŒã»ïŒâãžãšãã«âïœâãããã«ïŒâå°¿çŽ
ïŒååç©ïŒŠïŒ ïŒâïŒïŒâã¡ãã«âïŒâãšãã«âãã³ãã«ïŒâå°¿çŽ
ïŒååç©ïŒ§ïŒ ïŒâïŒïŒâïœâãããã«âïŒâã€ãœãããã«âïœ
âããã«ïŒâå°¿çŽ ïŒååç©ïŒšïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒã»ïŒâãžã¡ãã«âå°¿çŽ ïŒååç©ïŒ©ïŒ ïŒâïŒïŒã»ïŒâãžâïœâããã«âïœâãã³ãã«ïŒâ
å°¿çŽ ïŒååç©ïŒªïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒâã¡ãã«âå°¿çŽ ïŒååç©ïŒ«ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâããã
ã«ïŒâïŒâã¡ãã«âå°¿çŽ ïŒååç©ïŒ¬ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒâïŒïŒâããããã«ïŒâå°¿çŽ ïŒååç©ïŒïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒâïŒïŒâããããã«ïŒâå°¿çŽ ïŒååç©ïŒ®ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâã¡ãã«â
ïœâããã«ïŒâå°¿çŽ ïŒååç©ïŒ°ïŒ è¡åãžã®äœçš ç¥çµæ¯æ§ è¡ãªã€ãè©Šéšã¯ããã€ã·ã¢ïŒBOISSIERïŒã«
ããTherapie1958XIII第1074ã1118é ã«èšèŒ
ãããããŒã¿ããããã¹ãïŒrota rod testïŒ
ãšããŠç¥ãããŠãããã®ã§ããã ãã®è©Šéšã¯ãæ¯åïŒå転ã®é床ã§å転ããã
ãŒã©ãŒã®äžã«ããŠã¹ãã©ã®çšåºŠãšã©ãŸãããšã
ã§ããããïŒåé芳å¯ããããšã«ãããããŠã¹
ã®éå調æŽèœåã枬å®ããããšãç®çãšããã
ãã®è©Šéšã¯ãè©Šéšãã¹ãååç©ãçµå£æäžããŠ
30ååŸã«è¡ãã調æŽå€±æïŒfailureïŒã®çŸåçã
èšé²ããã çµæãäžè¡šã«ç€ºãã
çµæç©ã«é¢ããã æ¬çºæã®è¬ç掻æ§ã®ããå°¿çŽ èªå°äœã¯ã次ã®äž
è¬åŒ ãåŒäžR1ãR2åã³R3ã¯åäžåã¯çžç°ã€ãŠå€«ã ççŽ
æ°ïŒãïŒã®çŽéç¶åã¯åæç¶ã®ã¢ã«ãã«åºåã¯ã¢
ã«ããã«åºåã¯ïŒâããããã«åºããR4åã³R5
ã¯åäžåã¯çžç°ã€ãŠå€«ã æ°ŽçŽ åååã¯ççŽ æ°ïŒã
ïŒã®çŽéç¶åã¯åæç¶ã®ã¢ã«ãã«åºãã¢ã«ã±ãã«
åºåã¯ã¢ã«ããã«åºã瀺ããäœããR1ãR2åã³
R3ã«é¢ãã (a) ãã®ãã¡å¯äžã€ã®åºã®ã¿ããã¡ãã«å°¿çŽ åºã«
é¢ããŠÎ±ãβäœã«äžé£œåçµåãæããã¢ã«ãã
ã«åºã瀺ãããã®å Žåä»ã®ïŒã€ã®åºã¯å€«ã ã¢ã«
ãã«åºã瀺ããã®ãšããæŽã« (b) ãããåºã®ççŽ æ°ã®ç·åã¯ãïŒæªæºãšãªããª
ããã®ãšãããã ã§è¡šããããã äžè¬åŒïŒïŒã®ååç©ã®ãã¡ã«ã¯ãäžæŽççŽ ã
æãããã®ãå å«ãããŠãããæ¯ããååç©ã«é¢
ããŠã¯ããã®ã©ã»ãæ··åç©åã³çžåœããå åŠç°æ§
äœãæ¬çºæã«å å«ãããã åŸèšè©³è¿°ããæ§ã«ãæ¬çºæã®å°¿çŽ èªå°äœã¯ãé¡
èãªè¬çç¹æ§ãæããå»åŠåã³ç£å»åŠäžã®æ²»çç¹
ã«ç çäžå®åã³æ»ææ§ã®æ²»çã«æçšã§ããã åŸã€ãŠæ¬çºæã¯ãç çäžå®åã³æ»ææ§ã®æ²»çã«
䜿çšããè¬çåã¯ç£å»åŠççµæç©ãæäŸããããš
ããã®ç®çã®ïŒã€ãšããŠå å«ããã該çµæç©ã¯ã
å¿ é æå¹æåãšããŠäžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã®
å°ãªããšãäžçš®ãè¬çæ äœåã¯è³Šåœ¢å€ãšå ±ã«å«æ
ããã æ¬çºæã®ä»ã®ç®çã¯ãé©åœãªè¬çæ äœåã¯è³Šåœ¢
å€ãšå ±ã«äžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã®å°ãªããšã
ïŒçš®ãå«ããç çäžå®åã³æ»ææ§ã®æ²»ççšã®è¬ç
åã¯ç£å»åŠççµæç©ã®è£œé æ³ãæäŸããããšã§ã
ãã æŽã«æ¬çºæã®ä»ã®ç®çã¯ãæ²»çãå¿ èŠãšããŠã
ãæ£è ã«äžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã®å°ãªããšã
ïŒçš®ãæå¹éæäžããŠè©²æ£è ã®ç çäžå®åã³æ»æ
æ§ãæ²»çããæ¹æ³ãæäŸããããšã§ããã äœé60Kgã®äººã«æäžããå Žåãäžæ¥åœããæå¹
æå400ã1200mgã®æäžéã§æäžããã®ã奜ãŸã
ãã äžè¬åŒïŒïŒã®ååç©ã®äžã«ã¯ãæ¢ã«å è¡ç¹èš±
ãåè¡ç©ã«èšèŒãããŠå ¬ç¥ãšãªã€ããã®ãå«ãŸã
ãŠãããäŸãã°ãïŒâïŒïŒã»ïŒâãžâïœâããã«
âïœâãã³ãã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãžã¡ãã«
âïœâããã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãžã¡ãã«â
ïœâãããã«ïŒâå°¿çŽ ãïŒâïŒïŒâã¡ãã«âïŒâãš
ãã«âïœâãããã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãžã¡
ãã«âïœâãã³ãã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒã»ïŒã»
ïŒâããã©ã¡ãã«âïœâããã«ïŒâå°¿çŽ ãïŒâ
ïŒïŒã»ïŒã»ïŒã»ïŒâããã©ã¡ãã«âïœâãã³ã
ã«ïŒâå°¿çŽ åã³ïŒâïŒïŒã»ïŒâãžã¡ãã«âãšãã«ïŒ
âå°¿çŽ ã¯ç±³åœç¹èš±ç¬¬3847981å·ã«èšèŒãããŠã
ããããããªããããã®ç¹èš±ã«ã¯äžèšèªå°äœã®è¬
ç掻æ§ã«é¢ããŠã¯äœãèšèŒãããŠããªãã ã±ãã«ã« ã¢ãã¹ãã©ã¯ã80ã74ã36814jã«
ã¯ãïŒâïŒïŒâããããã«ïŒâå°¿çŽ ã®èªå°äœæ°çš®å³
ã¡ïŒâïŒïŒã»ïŒâãžã¡ãã«âïŒâããããã«ïŒâå°¿
çŽ ãïŒâïŒïŒâã¡ãã«âïŒâãšãã«âïŒâããã
ãã«ïŒâå°¿çŽ åã³ïŒâïŒïŒâã¡ãã«âïŒâïœâãã
ãã«âïŒâããããã«ïŒâå°¿çŽ ãèšèŒãããŠãã
ãããã®è¬çç¹æ§ã«é¢ããŠã¯äœãèšèŒããªãã åæ§ã«ãç±³åœç¹èš±ç¬¬3852473å·ã«ã¯ãïŒâïŒïŒã»
ïŒâãžã¡ãã«âãšãã«ïŒâå°¿çŽ ãïŒâïŒïŒã»ïŒâãž
ã¡ãã«âãããã«ïŒâå°¿çŽ åã³ïŒâïŒïŒâã¡ãã«â
ïŒâãšãã«âãããã«ïŒâå°¿çŽ ãèšèŒãããŠã
ãã該米åœç¹èš±ã«ã¯ãåèšäžè¬åŒïŒïŒã§è¡šãã
ããäžèšä»¥å€ã®èªå°äœãåç©äŸãã°çã®å€é£ãèª
çºããŠæé·ãä¿é²ãããè¬å€ãšãªãåŸãããšãè¿°
ã¹ãããŠãããããããªããæ¯ããç¹æ§ã¯äžèšïŒ
çš®ã®ååç©ã«ã€ããŠã®ã¿ç«èšŒãããŠããã ãã§ã
ããåŸã€ãŠãã®ç±³åœç¹èš±ã«å å«ãããèªå°äœå šãŠ
ãæ¯ããç¹æ§ãæããŠãããšã¯çµè«ã§ããªãã äžæ¹ãäžè¬åŒïŒïŒã®ååç©ã®äžã«ã¯ãå è¡æ
è¡ãšããŠåŒçšããåã¯èšèŒãããŠããããåŸã€ãŠ
æ°èŠååç©ã§ãããã®ãããã åŸã€ãŠæ¬çºæã¯ãäžè¬åŒïŒïŒã§è¡šããããæ°
èŠãªå°¿çŽ èªå°äœå³ã¡R1åã³R3ãåäžã§å€«ã ãšã
ã«åºåã¯ïœâãããã«åºããR2ããšãã«åºãïœ
âãããã«åºãã€ãœãããã«åºãïŒâã¡ãã«âã
ããã«åºãã¢ãªã«åºããšããã«åºãïŒâãããã
ã«åºåã¯ïŒâãããã«åºããR4ãæ°ŽçŽ ååãã¡
ãã«åºãã¢ãªã«åºåã¯ãããã«ã®ã«åºããR5ã
æ°ŽçŽ åååã¯ã¡ãã«åºã瀺ããã®ãæäŸããããš
ããã®ç®çã®ïŒã€ãšããŠå å«ããã ãã®ãã¡å¥œé©ãªååç©ã¯ãR1åã³R3ãåäžã§
ãšãã«åºåã¯ïœâãããã«åºããR2ããšãã«ã
ïœâãããã«ãã¢ãªã«ããšããã«ãïŒâãããã
ã«åã¯ïŒâãããã«ã®ååºããR4åã³R5ã倫ã
æ°ŽçŽ ååã瀺ããã®ã§ããã åã次ã®äžè¬åŒã§è¡šããããååç©ãæ¬çºæã®
奜é©ãªååç©ã§ãããå³ã¡ ãåŒäžR2ã¯ïœâãããã«ãã¢ãªã«ãïŒâãããã
ã«åã¯ïŒâãããã«ã®ååºã瀺ããã ã§è¡šããããååç©ã§ããã äžè¬åŒïŒïŒã®ååç©ã¯ãé©åœãªæº¶åªäŸãã°
æ°Žããšãã«ãšãŒãã«ãããã¿ã³ããã³ãŒã³ããã«
ãšã³çäžã§äžè¬åŒ ãåŒäžR1ãR2åã³R3ã¯äžè¬åŒïŒïŒã«ããããã
ããšåãã§ããã ã§è¡šããããã€ãœã·ã¢ããŒããšäžè¬åŒ R4âNHâR5 ïŒïŒ ãåŒäžR4åã³R5ã¯äžè¬åŒïŒïŒã«ãããããããš
åãã§ããã ã§è¡šããããååç©ãšãåå¿ãããããšã«ããåŸ
ãããããã®å Žåäžè¬åŒïŒïŒã®ã€ãœã·ã¢ããŒã
ããäžè¬åŒïŒïŒã®ååç©ãé©åœãªæº¶åªäžã«æº¶è§£
ããã溶液äžã«å ããã®ã奜ãŸãããåå¿æž©åºŠ
ã¯ã宀枩ä¹è³çšãã溶åªã®æ²žç¹ãŸã§ã®æž©åºŠã䜿çš
ã§ãããåãäžè¬åŒïŒïŒã®ååç©ãšããŠR4å
ã³R5ãæ°ŽçŽ ååã瀺ããã®å³ã¡ã¢ã³ã¢ãã¢ã䜿
çšããå Žåã«ã¯ãæ°Žåã¯ææ©æº¶åªäŸãã°ãžãªããµ
ã³çã«æº¶è§£ãããç¶æ ã§å ããã ä»ã®æ¹æ³ã«äŸãã°ãR4åã³R5ã倫ã æ°ŽçŽ åå
ã§ããäžè¬åŒïŒïŒã®ååç©ã¯ãäžè¬åŒ ãåŒäžR1ãR2åã³R3ã¯äžè¬åŒïŒïŒã®å Žåãšåã
ã§ããã ã§è¡šããããã¡ãã«ã¢ãã³èªå°äœããããå°¿çŽ ãš
å ±ã«å ç±ããããšã«ããåŸãããã奜ãŸããã¯ã
åå¿ãæ°Žäžã§30ã70â奜ãŸããã¯çŽ50âã®æž©åºŠäž
ã«è¡ãªãã®ãããããã®æ¹æ³ã¯ãç¹ã«ããªâ眮æ
ã¡ãã«å°¿çŽ åºã«é¢ããŠÎ±ã»Î²âäœã«äžé£œåçµåã
æããæ¬çºæã®å°¿çŽ èªå°äœã補é ããã®ã«çšãã
ããã åæ§ã«äžè¬åŒïŒïŒã®ååäžR4ãççŽ æ°ïŒã
ïŒã®çŽéåã¯åæã®ã¢ã«ãã«åºãã¢ã«ã±ãã«åºå
ã¯ã¢ã«ããã«åºããR5ãæ°ŽçŽ ååã瀺ããã®
ã¯ã宀枩äžåã¯å ç±äžäŸãã°ãšãã«ãšãŒãã«çã®
é©åœãªæº¶åªäžã§äžè¬åŒïŒïŒã§è¡šããããã¡ãã«
ã¢ãã³èªå°äœãšäžè¬åŒ R4âïŒïŒ£ïŒïŒ¯ ïŒïŒ ãåŒäžR4ã¯äžèšã«åãã ã§è¡šããããã€ãœã·ã¢ããŒããšãåå¿ãããããš
ã«ããåŸããããåå¿æž©åºŠã¯äœ¿çšããåå¿è©Šè¬ã«
ããç°ãªããã宀枩ãã110âã®æž©åºŠã奜ãŸã
ããåãäžè¬åŒïŒïŒã®ã€ãœã·ã¢ããŒããé©åœãª
溶åªã«æº¶è§£ããã溶液äžã«äžè¬åŒïŒïŒã®ã¢ãã³
ãå ããã®ã奜ãŸããã äžè¬åŒïŒïŒåã³ïŒïŒã®ååç©ã®äžã«ã¯ãç±³
åœç¹èš±ç¬¬4026925å·ã«èšèŒãããŠãããã®ãã
ãããã®ä»ã®äžè¬åŒïŒïŒåã³ïŒïŒã®ååç©ã¯
該米åœç¹èš±ã«èšèŒã®æ¹æ³ã«ãã補é ããããšãã§
ããã äžæ¢ç¥çµç³»ã«é¢ããè¬çç¹æ§ãã詳ããã¯ç²Ÿç¥
å®å®ãäžå®é€å»ãçèæœç·©ãé®éãå¬ç åã³æç
æ£ã®åäœçšãæããå°¿çŽ èªå°äœã¯å ¬ç¥ã§ããã ãã®èªå°äœã®æçš®ã®ãã®äŸãã°ããšãã«ã¢ã»ã
ã«å°¿çŽ ãããã¢ãžãšãã«ã¢ã»ãã«å°¿çŽ ãαâãã
ã¢ã€ãœãã¬ãªã«å°¿çŽ çã¯æ¢ã«åžè²©ãããŠãããä»
ã®ãã®ã¯äŸãã°ç±³åœç¹èš±ç¬¬2999110å·åã³ç¬¬
3110728å·ãè±åœç¹èš±ç¬¬1056833å·ããã©ã³ã¹åœç¹
蚱第5431 ïŒå·åã³ãã€ãæ°äž»å ±ååœç¹èš±ç¬¬21573
å·çã®å è¡ç¹èš±åã¯å è¡åè¡ç©ã«èšèŒãããŠã
ãã äžèšç¹èš±ã«ãããŠç²Ÿç¥å®å®å€åã¯äžå®é€å»å€ãš
ããŠèšèŒãããŠããå°¿çŽ èªå°äœã¯ããã®ååäž
ã«ãå°¿çŽ åºãæ§æãããã®ä»¥å€ã®ãããååãæ
ããŠããããšã«ããç¹åŸŽä»ãããããå³ã¡ããã²
ã³ååãé žçŽ ååããç¹ã«ã«ã«ããã«åºåã¯ãã
ããã·ã«åºã®åœ¢ã§å«ãã§ããã æŽã«ãtertâããã«âå°¿çŽ ã¯ãArch.Int.
Pharmacodyn.219ã103â115ïŒ1976ïŒã«æçæ£ã
å¬ç åã³é®éã®åäœçšãæããè¬å€ãšããŠåã³ã
ã«ãããŒã«é žå¡©ã®å¬ç äœçšã®çžä¹äœçšå€
ïŒPotentiatorïŒãšããŠèšèŒãããŠãããåãïœâ
ããã«âå°¿çŽ ããArch.Int.Pharmaeodyn208ã
204â212ïŒ1974ïŒã«tertâããã«âå°¿çŽ ãšåæ§ãª
äœçšãæããããšãèšãããŠããã ããããªããä¹çåè¡ç©ã¯ãïœâããã«âå°¿çŽ
åã¯tertâããã«âå°¿çŽ ãäžå®é€å»
ïŒanxiolyticïŒåã¯ææ»æäœçšãæããããšã瀺å
ãããã®ã§ã¯ãªãã ïŒçš®ã®å°¿çŽ èªå°äœããChimie Therapeutigue
No.4ãpp.412ã418ã«èšãããŠããããã®ãã¡ã®
ïŒçš®ã¯ïŒâïŒïŒâã¡ãã«âïŒâãããã«âãã³ã
ã«ïŒâïŒâã·ã¯ãããã·ã«âå°¿çŽ ã§ããããã®æ
ç®ã¯ãäžèšïŒçš®ã®ååç©ã«é¢ããæ°çš®ã®è¬çè©Šéš
ã«ã€ããŠèšèŒãããã®ã§ãããããããªãããäž
å®é€å»æ§åã¯ææ»ææ§ã®éç¥å®å®äœçšã«ã€ããŠã¯
äœãè¿°ã¹ãããŠããªãã ãšãããé©ãã¹ãäºã«ãïŒâïŒïŒâã¡ãã«âïŒ
âãããã«âãã³ãã«ïŒâïŒâã·ã¯ãããã·ã«â
å°¿çŽ ãtertâããã«âå°¿çŽ åã³ïœâããã«âå°¿çŽ
ãšé¡äŒŒã®ååŠæ§é ãæããäžã€ãããååããª
ããåã«èèªæçåæ°ŽçŽ åºãæããããšãç¹åŸŽãš
ããäžè¬åŒïŒïŒã®å°¿çŽ èªå°äœã¯ãæçšãªäžå®é€
å»åã³ææ»æäœçšãçºæ®ããããšãå€æããã ã¡ãã«å°¿çŽ ã®ããªãŒçœ®æèªå°äœã¯ãéç¥å®å®å€
åã¯äžå®é€å»å€ãšããŠæå¹ãªå°¿çŽ èªå°äœãéåžžæ
ãã眮æåºãïŒâäœã«æããŠããç¹ã§äžè¬åŒ
ïŒïŒã§è¡šããããèªå°äœãšé¡äŒŒããã«ãããã
ãããäžå®é€å»åã¯ææ»æäœçšã«é¢ããŠã¯äžæŽ»æ§
ã§ãããåã¯å®è³ªçã«æ¯ããäœçšãæããªããã
ã®ããšãèæ ®ãããšãäžèšç¥èŠã¯å®ã«äºæ³å€ã®ã
ãšã§ããã å ããŠãæ¬çºæååç©ã¯ãè¡ååã³éååã«åœ±
é¿ãäžããªãéã®æäžéã§äžå®é€å»äœçšãçºæ®ã
ãã®ã§ããããã®äºå®ã¯ãå è¡æè¡ç¹ã«ãã©ã³ã¹
å»è¬ç¹å¥ç¹èš±ç¬¬5341 ïŒå·ããã¯å šãäºæž¬ã§ããª
ãããšã§ãããäºå®ã該ãã©ã³ã¹å»è¬ç¹å¥ç¹èš±ã«
å å«ãããèªå°äœã¯ãé®éæäžéïŒsedative
dosesïŒã§äžå®é€å»äœçšãæãããšèšãããŠã
ãã æ¯ãããŠãé®éäœçšããäžå®é€å»äœçšãåé¢ã
åŸããšããæ¬çºæååç©ã«ããããããããå¹æ
ã¯ãäžèšãã©ã³ã¹å»è¬ç¹å¥ç¹èš±ã«å å«ãããåå
ç©åã³æãçš®ã®åžè²©ååç©äŸãã°ãžã¢ãŒãã
ïŒdiazepamïŒãã¡ãããã¡ãŒãïŒmeprobamateïŒ
çã«æ¯ã極ããŠåªããå©ç¹ãããã æãçšåºŠã®åŸç åã³æ³šæéäžåã®åªå€±ããä¹ç
粟ç¥å®å®å€ã®æ¬ ç¹ã§ããããšãç¥ããŠããããã®
çºã«ãç·»å¯ãªæ³šæåãèŠããè·æ¥ã«å°±ããŠãã人
ãèªåè»ã®é転æçãå€æ¥éé¢æ²»çããå ŽåïŒin
ambulatory therapyïŒã«ã¯æ éããèŠããã®ã§
ããã ããã«å¯Ÿããæ¬çºæååç©ã¯ãåŸæ¥ã®æ²»çæ³ã«
æ¯ãæçšãªå©ç¹ããããããå³ã¡ãæ¬çºæååç©
ã¯ãäžå®é€å»ã«æå¹ãªæäžéã«ãããŠé®éåã¯å¬
ç äœçšãå šãåãŒããªãã®ã§ãããåŸã€ãŠæ¬çºæ
ååç©ã䜿çšããå Žåã«ã¯ã泚æéäžåã«åœ±é¿ã
äžãããåŸã€ãŠåŸæ¥å ¬ç¥ã®äžå®é€å»å€ãçšããå Ž
åã«æ¹èµ·ããããæ²»çã®åŠšããšãªãæãçš®ã®çŠå¿
ãåé¿ããããšãã§ããã æ¬çºæååç©ã«ã¯ãæŽã«ã極ããŠæ¯æ§ãäœããš
ããç¹åŸŽãããããã®å©ç¹ã¯ç²Ÿç¥å»åŠã®åéã§ç¹
ã«éèŠæ§ãããããªããªãã°ããã®åéã«ãããŠ
ã¯éå°æäžã«ããèªæ®ºè¡åãæ¹èµ·ããããšããã°
ãã°ããããã§ããã æŽã«ãæ¬çºæååç©ã粟ç¥å®å®äœçšãçºæ®ãã
éæäžïŒtranguillising dosesïŒããå Žåãäžæ¢
åã¯æ«æ¢¢ã³ãªã³æå¶æ§äœçšã«åž°å ãã奜ãŸãããª
ãå¯äœçšäŸãã°å£å 也ç¥ãèŠèŠèª¿ç¯ïŒoptical
accommodationïŒã®å°é£ãçºæ±ãé »èçãäœãæ¹
èµ·ããªãã ãã®èŠ³ç¹ãããæ¬çºæååç©ã¯æçšã§ãå»åž«ã¯
æã®ãŸãŸã«æ²»çãè¡ãªãããšãã§ãããå¿ èŠãšã
ãã°ãäŸãã°æ£è ã®ç¶æ å€åãç¿æ £æ§çäœããã®
çç±ã§äœ¿çšã§ããªããã®ãšãªã€ãè¬å€ã«ä»£ããŠæ¬
çºæååç©ãçšããŠæ²»çãè¡ãªãåŸãã æ¬çºæååç©äžãæãé¡èãªäžå®é€å»åã³ææ»
æäœçšã瀺ããã®ã¯ãïŒâïŒïŒã»ïŒâãžâïœâã
ããã«âïœâããã«ïŒâå°¿çŽ å³ã¡ããªâïœâãã
ãã«ã¡ãã«å°¿çŽ ã§ããã æ¬çºæã®ãã®å¥œé©ãªååç©ã«ã€ããŠæŽã«è¬çè©Š
éšãè¡ã€ãæãéé®éæäžéã§ã¯ãã«ãããŒã«é ž
å¡©ã®å¬ç äœçšäžŠã³ã«ã¡ãããã¡ã€ãåã³ãžã¢ãŒã
ã çã®ç²Ÿç¥å®å®å€ã®é®éäœçšã«å¯Ÿãçžä¹äœçšã瀺
ããæŽã«ã該ååç©ã¯ãšã¿ããŒã«ã®äœçšã«å¯ŸããŠ
ã¯ãããããçžä¹äœçšã瀺ããªãã€ãã æŽã«æ¬çºæã®å¥œé©ååç©ã¯ãå¿èµè管系åã¯åŒ
åžåšç³»ã«å¯ŸããŠåœ±é¿ãåãŒããªããäºå®ãæ¬çºæ
ã®äžèšå¥œé©ååç©ã¯ã麻é ããã©ããã«100mg/Kg
åã³200mg/Kgè ¹è å æäžããå Žåã該ã©ããã®å š
身系åèè¡å§ãå¿ææ°åã³åŒåžæ°ãå€åãããª
ãã åæ§ã«ãæ¬çºæã®äžèšå¥œé©ååç©ãã©ããã«
100mg/Kgæäžããå Žåãã¢ã»ãã«ã³ãªã³ã«ããèª
çºãããäœè¡å§çåã³åŸèã«å¯Ÿãäœã®åœ±é¿ãäžã
ãªããåéå³ã¡200mg/Kgãè ¹è å 泚å°ããå Žåã«
ãããšããããªã³ã«ããæ¹èµ·ãããαâã¢ãã¬ã
ãªã³äœåæ§äœçšåã¯Î²âã¢ãã¬ããªã³äœåæ§äœçš
ãå€åãããªããæ¬çºæã®å¥œé©ååç©ã¯ä¹ç奜ãŸ
ãããªãå¯äœçšãæããªãçºãå¿èé害åã³åè
è¡å§ã®é害ãæ¹èµ·ããªãã æ¬çºæååç©ã®æ¯æ§ã調ã¹ãçºåæ¬çºæååç©
ã粟ç¥å®å®å€ãšããŠæçšãªä»ã®ç¹æ§ãæãããåŠ
ãã«ã€ããŠè¬çè©Šéšãè¡ã€ãã äŸãšããŠäžèšååç©ã«ã€ããŠåŸãããè©Šéšçµæ
ã次ã«è¿°ã¹ãã ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
å°¿çŽ ïŒååç©ïŒ¡ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâãã³ãã
ã«ïŒâå°¿çŽ ïŒååç©ïŒ¢ïŒ ïŒâïŒïŒã»ïŒâãžãšãã«âïŒâããããã«ïŒâå°¿çŽ
ïŒååç©ïŒ£ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâããã
ã«ïŒâå°¿çŽ ïŒååç©ïŒ€ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâããã
ã«ïŒâå°¿çŽ ïŒååç©ïŒ¥ïŒ ïŒâïŒïŒã»ïŒâãžãšãã«âïœâãããã«ïŒâå°¿çŽ
ïŒååç©ïŒŠïŒ ïŒâïŒïŒâã¡ãã«âïŒâãšãã«âãã³ãã«ïŒâå°¿çŽ
ïŒååç©ïŒ§ïŒ ïŒâïŒïŒâïœâãããã«âïŒâã€ãœãããã«âïœ
âããã«ïŒâå°¿çŽ ïŒååç©ïŒšïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒã»ïŒâãžã¡ãã«âå°¿çŽ ïŒååç©ïŒ©ïŒ ïŒâïŒïŒã»ïŒâãžâïœâããã«âïœâãã³ãã«ïŒâ
å°¿çŽ ïŒååç©ïŒªïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒâã¡ãã«âå°¿çŽ ïŒååç©ïŒ«ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâããã
ã«ïŒâïŒâã¡ãã«âå°¿çŽ ïŒååç©ïŒ¬ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒâïŒïŒâããããã«ïŒâå°¿çŽ ïŒååç©ïŒïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâããã«ïŒâ
ïŒâïŒïŒâããããã«ïŒâå°¿çŽ ïŒååç©ïŒ®ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïŒâã¡ãã«â
ïœâããã«ïŒâå°¿çŽ ïŒååç©ïŒ°ïŒ è¡åãžã®äœçš ç¥çµæ¯æ§ è¡ãªã€ãè©Šéšã¯ããã€ã·ã¢ïŒBOISSIERïŒã«
ããTherapie1958XIII第1074ã1118é ã«èšèŒ
ãããããŒã¿ããããã¹ãïŒrota rod testïŒ
ãšããŠç¥ãããŠãããã®ã§ããã ãã®è©Šéšã¯ãæ¯åïŒå転ã®é床ã§å転ããã
ãŒã©ãŒã®äžã«ããŠã¹ãã©ã®çšåºŠãšã©ãŸãããšã
ã§ããããïŒåé芳å¯ããããšã«ãããããŠã¹
ã®éå調æŽèœåã枬å®ããããšãç®çãšããã
ãã®è©Šéšã¯ãè©Šéšãã¹ãååç©ãçµå£æäžããŠ
30ååŸã«è¡ãã調æŽå€±æïŒfailureïŒã®çŸåçã
èšé²ããã çµæãäžè¡šã«ç€ºãã
ãè¡šã
ãã®è©Šéšçµæã¯ïŒã€ã®æå³ãæãããããŠã¹
ã®å€±æã¯ãä»ã®æ¹æ³ã§ã¯èå¥ã§ããªãçç¥çµãž
ã®åŸ®å°ãªæå·ãäžæ©ã衚瀺ãããã®ã§ããã第
ïŒã«ããã®è©Šéšã¯ãä»ã®è©Šéšçµæãå å«ããæ
æ°ãåŸãããã®æ¯èŒèŠçŽ ãšãªãã ååç©ïŒ¡ã«ã€ããŠæŽã«è¡åè©Šéšãè¡ã€ããäŸ
ãã°ã該ååç©ã175mg/Kgçµå£æäžããŠ60å
åŸãããŠã¹ã®èªçºéååïŒspontaneous
motoricityïŒã¯ããã12ïŒ ãšããææã§ãªãæž
å°ã瀺ããããã®è©Šéšã¯ãç±³åœç¹èš±ç¬¬3929869
å·ã«èšèŒãããŠããã 平衡æèŠäžŠã³ã«çã®ç·åŒµåã³åŒ·åºŠã枬å®ãã
ããšãã§ããçœåŒè©ŠéšïŒtraction testïŒ
ïŒPsychotropic Drugsã1957ã373â391ïŒãå
åç©ïŒ¡ã«ã€ããŠè¡ãªã€ãæãED50å³ã¡è©Šéšã«
ãããŠ50ïŒ å€±æãæ¹èµ·ããæäžéïŒæäž60å
åŸïŒã¯ãããŠã¹ã«å¯Ÿãçµå£æäžã§600mg/Kgã§ã
ã€ãã ããŠã¹ã«ãããååç©ïŒ¡ã®å¬ç äœçšã姿å¢å
å°ã®è©Šéšã«ããè©ŠéšãããããŠã¹ã®èŠ³å¯ã¯ãå
åç©ïŒ¡ã®æäžåŸïŒæéç¶ããããã®çµæãæ倧
ã®æäžéå³ã¡1000mg/Kgã®æäžéã«ãããŠã姿
å¢åå°ã¯å šãæ¶å€±ããªãã€ãã 粟ç¥å®å®æ§ç¹æ§ã®æž¬å®  äžå®é€å»äœçš äžå®é€å»äœçšã¯ã(a)é»æéäºè©Šéš
ïŒelectricallyâprovoked combat testïŒïŒJ.
Pharmacol.Exp.Therap.1959ã125â128ïŒå
ã³(b)ããªãŒãã¬ãŒãè©ŠéšïŒfour platestestïŒ
ïŒEuropean J.Pharmacol.1968ãïŒã141â
151ïŒã«ããæããã«ãããã (a) æãæ¡ä»¶äžã§äžå¯Ÿã®ããŠã¹ã«é»æ°ã·ãšã
ã¯ãäžãããšãããŠã¹ã¯ããã®äžå®ã«ãã
æ¹èµ·ãããäžé£ã®éäºãè¡ãªãããã®äžå®
ã¯ãããäžå¹ã®ããŠã¹ãšã®éäºã«ããè¡šã
ãããããã®çç±ãããé»æéäºè©Šéšã¯ã
ååç©ã®äžå®é€å»äœçšãè©äŸ¡ããæ段ãšè
ããããã äºåã«æ°Žã ãããäžããããŠããªãã€ã
ïŒå¹ã®ããŠã¹ãïŒã€ã®ã«ãŽã«å ¥ãããä¹ç
ããŠã¹ã«ããã®æææ§ã«å¿ã40ã80ãã«ã
ã®åŒ·åºŠã®äžé£ã®é»æ°è¡æãäžãããå ã察
ç §ãšããŠç¡åŠçã®ããŠã¹ã«ã€ããŠã次ãã§
è©Šéšãã¹ãååç©ãè©Šéšã®30ååã«æäžã
ãŠåŠçããåäžã®ããŠã¹ã«ã€ããŠè©Šéšã
ãã çããéäºæ°ãèšé²ãããçµæã¯ãåŠç
ããŠã¹ã«ããè¡ãªãããéäºæ°ã®æžå°ãã
åŠçåã®ããŠã¹ã®éäºæ°ãšæ¯èŒããŠçŸåç
ã§è¡šãããã çµæãäžèšã«ç€ºãã
ã®å€±æã¯ãä»ã®æ¹æ³ã§ã¯èå¥ã§ããªãçç¥çµãž
ã®åŸ®å°ãªæå·ãäžæ©ã衚瀺ãããã®ã§ããã第
ïŒã«ããã®è©Šéšã¯ãä»ã®è©Šéšçµæãå å«ããæ
æ°ãåŸãããã®æ¯èŒèŠçŽ ãšãªãã ååç©ïŒ¡ã«ã€ããŠæŽã«è¡åè©Šéšãè¡ã€ããäŸ
ãã°ã該ååç©ã175mg/Kgçµå£æäžããŠ60å
åŸãããŠã¹ã®èªçºéååïŒspontaneous
motoricityïŒã¯ããã12ïŒ ãšããææã§ãªãæž
å°ã瀺ããããã®è©Šéšã¯ãç±³åœç¹èš±ç¬¬3929869
å·ã«èšèŒãããŠããã 平衡æèŠäžŠã³ã«çã®ç·åŒµåã³åŒ·åºŠã枬å®ãã
ããšãã§ããçœåŒè©ŠéšïŒtraction testïŒ
ïŒPsychotropic Drugsã1957ã373â391ïŒãå
åç©ïŒ¡ã«ã€ããŠè¡ãªã€ãæãED50å³ã¡è©Šéšã«
ãããŠ50ïŒ å€±æãæ¹èµ·ããæäžéïŒæäž60å
åŸïŒã¯ãããŠã¹ã«å¯Ÿãçµå£æäžã§600mg/Kgã§ã
ã€ãã ããŠã¹ã«ãããååç©ïŒ¡ã®å¬ç äœçšã姿å¢å
å°ã®è©Šéšã«ããè©ŠéšãããããŠã¹ã®èŠ³å¯ã¯ãå
åç©ïŒ¡ã®æäžåŸïŒæéç¶ããããã®çµæãæ倧
ã®æäžéå³ã¡1000mg/Kgã®æäžéã«ãããŠã姿
å¢åå°ã¯å šãæ¶å€±ããªãã€ãã 粟ç¥å®å®æ§ç¹æ§ã®æž¬å®  äžå®é€å»äœçš äžå®é€å»äœçšã¯ã(a)é»æéäºè©Šéš
ïŒelectricallyâprovoked combat testïŒïŒJ.
Pharmacol.Exp.Therap.1959ã125â128ïŒå
ã³(b)ããªãŒãã¬ãŒãè©ŠéšïŒfour platestestïŒ
ïŒEuropean J.Pharmacol.1968ãïŒã141â
151ïŒã«ããæããã«ãããã (a) æãæ¡ä»¶äžã§äžå¯Ÿã®ããŠã¹ã«é»æ°ã·ãšã
ã¯ãäžãããšãããŠã¹ã¯ããã®äžå®ã«ãã
æ¹èµ·ãããäžé£ã®éäºãè¡ãªãããã®äžå®
ã¯ãããäžå¹ã®ããŠã¹ãšã®éäºã«ããè¡šã
ãããããã®çç±ãããé»æéäºè©Šéšã¯ã
ååç©ã®äžå®é€å»äœçšãè©äŸ¡ããæ段ãšè
ããããã äºåã«æ°Žã ãããäžããããŠããªãã€ã
ïŒå¹ã®ããŠã¹ãïŒã€ã®ã«ãŽã«å ¥ãããä¹ç
ããŠã¹ã«ããã®æææ§ã«å¿ã40ã80ãã«ã
ã®åŒ·åºŠã®äžé£ã®é»æ°è¡æãäžãããå ã察
ç §ãšããŠç¡åŠçã®ããŠã¹ã«ã€ããŠã次ãã§
è©Šéšãã¹ãååç©ãè©Šéšã®30ååã«æäžã
ãŠåŠçããåäžã®ããŠã¹ã«ã€ããŠè©Šéšã
ãã çããéäºæ°ãèšé²ãããçµæã¯ãåŠç
ããŠã¹ã«ããè¡ãªãããéäºæ°ã®æžå°ãã
åŠçåã®ããŠã¹ã®éäºæ°ãšæ¯èŒããŠçŸåç
ã§è¡šãããã çµæãäžèšã«ç€ºãã
ãè¡šã
ãè¡šã
åäžè©Šéšæ¡ä»¶äžã§è¡ã€ãæ¯èŒã«äŸãã°ã
ãžã¢ãŒãã åã³ã¡ãããã¡ãŒãã¯å€«ã 0.69
mg/Kgåã³70mg/Kgã®æäžéã§äžå®ã«å¯Ÿã50
ïŒ ã®ä¿è·ãäžããã æŽã«ãååéšA.ãžã¢ãŒãã åã³ã¡ãã
ãã¡ãŒã倫ã ã®éäºã60ïŒ æžå°ãããæäž
éã«ãããŠè¡ã€ãããŒã¿ãããè©Šéšã«äŸã
ã°ãååç©ïŒ¡ã®å Žå倱æã¯å šãèŠãããªã
ã€ããããžã¢ãŒãã åã³ã¡ãããã¡ãŒãã®
å Žå倫ã 12ïŒ åã³35ïŒ ã®å€±æã芳å¯ãã
ãã åæ§ã«ãååç©ïŒ¡ã¯èªçºéååã«äœçšã
ãããšãªãéäºæ°ã80ïŒ æžå°ããããããž
ã¢ãŒãã ã¯èªçºéååãå€åãããããšãª
ãéäºæ°ã15ïŒ ä»¥äžæžå°ãããããšã¯ã§ã
ãªããåŸã€ãŠãäŸãã°éäºæ°ã80ïŒ æžå°ã
ããæäžéã«ãããŠã¯ããžã¢ãŒãã ã¯èªçº
éååã40ïŒ æžå°ãããã®ã§ããã (b) ããªãŒãã¬ãŒãè©Šéšã¯ãäžå®é€å»æ§ãèŠ
ãã®ã«å¥œé©ã§ãããè©Šéšãã¹ãååç©ãã
ãŠã¹ã«ãçµå£æäžããŠ30ååŸã«è©Šéšããã å ããããªãé«ãå£ãåããåºã«ïŒã€ã®
æ£æ¹åœ¢ã®ãã¬ãŒããèšããç®±ã®äžã«ããŠã¹
ãå ¥ãããä¹çãã¬ãŒãã¯å€«ã åäžã®å€§ã
ããæããäžå¿è»žã«ããäºãã«åé¢ãããŠ
ãããé»æºã®éœæ¥µåã³é°æ¥µã«ãã亀äºã«é»
æ°ããããããšãã§ãããé£æ¥ãããã¬ãŒ
ãéã®ééã¯æ°mmã§ããã ãã®è£ 眮ã«å ¥ããããããŠã¹ã¯ãè©²è£ çœ®
ãèžæ»ãïŒexploreïŒãåŒç¶ããŠç°ãªããã¬
ãŒãäžãééããããã«ãªããïŒåéã«ã
ãŠã¹ããã¬ãŒãäžãééããåæ°ãèšé²ã
ãã次ãã§é»æµãéãããšããã¬ãŒãäžã
ééããŠããããŠã¹ã«é»æ°ã·ãšãã¯
ïŒ80VïŒãäžããããèžæ»è¡åãæžå°ãã
éã«ã¯å®å šã«åæ¢ããŠããŸãã äžå®é€å»å€ã¯ãããŠã¹ãäžèšé»æ°ã·ãšã
ã¯ã«å¯Ÿãå€ããå°ãªããç¡é¢å¿ã«ãããã
ãã®çµæãäžå®é€å»å€ãæäžãããããŠã¹
ã®ãã¬ãŒãäžãééããåæ°ã¯ãé»æ°ã·ãš
ãã¯ã«ãããããããã·ãšãã¯ãåããªã
ã€ãå¯Ÿç §ããŠã¹ã®å Žåã®åæ°ã«è¿ä»ãåŸå
ã瀺ãã æ¬çºæååç©ã®äžå®ã«å¯Ÿããä¿è·ã®çŸå
çã¯ãé»æ°ãããããããã¬ãŒãäžãå¯Ÿç §
ããŠã¹ãééããåæ°ãšæ¬çºæååç©ãæ
äžãããããŠã¹ãééããåæ°ãšãæ¯èŒã
ãããšã«ããåŸããçµæãäžè¡šã«ç€ºãã
ãžã¢ãŒãã åã³ã¡ãããã¡ãŒãã¯å€«ã 0.69
mg/Kgåã³70mg/Kgã®æäžéã§äžå®ã«å¯Ÿã50
ïŒ ã®ä¿è·ãäžããã æŽã«ãååéšA.ãžã¢ãŒãã åã³ã¡ãã
ãã¡ãŒã倫ã ã®éäºã60ïŒ æžå°ãããæäž
éã«ãããŠè¡ã€ãããŒã¿ãããè©Šéšã«äŸã
ã°ãååç©ïŒ¡ã®å Žå倱æã¯å šãèŠãããªã
ã€ããããžã¢ãŒãã åã³ã¡ãããã¡ãŒãã®
å Žå倫ã 12ïŒ åã³35ïŒ ã®å€±æã芳å¯ãã
ãã åæ§ã«ãååç©ïŒ¡ã¯èªçºéååã«äœçšã
ãããšãªãéäºæ°ã80ïŒ æžå°ããããããž
ã¢ãŒãã ã¯èªçºéååãå€åãããããšãª
ãéäºæ°ã15ïŒ ä»¥äžæžå°ãããããšã¯ã§ã
ãªããåŸã€ãŠãäŸãã°éäºæ°ã80ïŒ æžå°ã
ããæäžéã«ãããŠã¯ããžã¢ãŒãã ã¯èªçº
éååã40ïŒ æžå°ãããã®ã§ããã (b) ããªãŒãã¬ãŒãè©Šéšã¯ãäžå®é€å»æ§ãèŠ
ãã®ã«å¥œé©ã§ãããè©Šéšãã¹ãååç©ãã
ãŠã¹ã«ãçµå£æäžããŠ30ååŸã«è©Šéšããã å ããããªãé«ãå£ãåããåºã«ïŒã€ã®
æ£æ¹åœ¢ã®ãã¬ãŒããèšããç®±ã®äžã«ããŠã¹
ãå ¥ãããä¹çãã¬ãŒãã¯å€«ã åäžã®å€§ã
ããæããäžå¿è»žã«ããäºãã«åé¢ãããŠ
ãããé»æºã®éœæ¥µåã³é°æ¥µã«ãã亀äºã«é»
æ°ããããããšãã§ãããé£æ¥ãããã¬ãŒ
ãéã®ééã¯æ°mmã§ããã ãã®è£ 眮ã«å ¥ããããããŠã¹ã¯ãè©²è£ çœ®
ãèžæ»ãïŒexploreïŒãåŒç¶ããŠç°ãªããã¬
ãŒãäžãééããããã«ãªããïŒåéã«ã
ãŠã¹ããã¬ãŒãäžãééããåæ°ãèšé²ã
ãã次ãã§é»æµãéãããšããã¬ãŒãäžã
ééããŠããããŠã¹ã«é»æ°ã·ãšãã¯
ïŒ80VïŒãäžããããèžæ»è¡åãæžå°ãã
éã«ã¯å®å šã«åæ¢ããŠããŸãã äžå®é€å»å€ã¯ãããŠã¹ãäžèšé»æ°ã·ãšã
ã¯ã«å¯Ÿãå€ããå°ãªããç¡é¢å¿ã«ãããã
ãã®çµæãäžå®é€å»å€ãæäžãããããŠã¹
ã®ãã¬ãŒãäžãééããåæ°ã¯ãé»æ°ã·ãš
ãã¯ã«ãããããããã·ãšãã¯ãåããªã
ã€ãå¯Ÿç §ããŠã¹ã®å Žåã®åæ°ã«è¿ä»ãåŸå
ã瀺ãã æ¬çºæååç©ã®äžå®ã«å¯Ÿããä¿è·ã®çŸå
çã¯ãé»æ°ãããããããã¬ãŒãäžãå¯Ÿç §
ããŠã¹ãééããåæ°ãšæ¬çºæååç©ãæ
äžãããããŠã¹ãééããåæ°ãšãæ¯èŒã
ãããšã«ããåŸããçµæãäžè¡šã«ç€ºãã
ãè¡šã
æ¯èŒã®ãããããªãŒãã¬ãŒãè©Šéšã«ãã
ãŠ25ïŒ ã®ä¿è·ã瀺ãæäžéã®ãžã¢ãŒãã å
ã³ã¡ãããã¡ãŒãã«ã€ããããŒã¿ãããè©Š
éšåã³èªçºéååã«é¢ããè©Šéšãè¡ãªã€
ãã ãã®æ¯èŒã«ãããŠED25ãçšããã®ã¯ã
ãžã¢ãŒãã ãïŒmg/Kg以äžæäžããå Žåã
ãã®ééäœçšã匷ãããçºãžã¢ãŒãã ã®
ED50ãåŸãããªãã€ãããã§ãããçµæ
ããååç©ïŒ¡ã«é¢ãåŸãããçµæãšäœµèšã
ãŠäžè¡šã«ç€ºãã
ãŠ25ïŒ ã®ä¿è·ã瀺ãæäžéã®ãžã¢ãŒãã å
ã³ã¡ãããã¡ãŒãã«ã€ããããŒã¿ãããè©Š
éšåã³èªçºéååã«é¢ããè©Šéšãè¡ãªã€
ãã ãã®æ¯èŒã«ãããŠED25ãçšããã®ã¯ã
ãžã¢ãŒãã ãïŒmg/Kg以äžæäžããå Žåã
ãã®ééäœçšã匷ãããçºãžã¢ãŒãã ã®
ED50ãåŸãããªãã€ãããã§ãããçµæ
ããååç©ïŒ¡ã«é¢ãåŸãããçµæãšäœµèšã
ãŠäžè¡šã«ç€ºãã
ãè¡šã
以äžã®çµæãããååç©ïŒ¡ã¯æãé®éäœçš
ãå°ãããç¹ã«ããŒã¿ãããè©Šéšã«ããã倱
æçãæ¯èŒããå Žåã«ã¯ãããé¡èã§ããã
æŽã«ãããªãŒãã¬ãŒãè©Šéšã«ãããŠãååç©
ã«ã€ããŠã¯é®éäœçšãäœã瀺ãããšãªã奜
é©ãªçµæãåŸããããããã¯ãã¡ãããã¡ãŒ
ãåã³ãžã¢ãŒãã ã§ã¯åŸãããªãã€ãã ååç©ïŒ«ã亊ããžã¢ãŒãã åã³ã¡ãããã¡
ãŒãã«æ¯ãäœãé®éäœçšãæããŠããããšã
å€ã€ããå³ã¡ããŠã¹ã«300mg/KgïŒããªãŒãã¬
ãŒãè©Šéšã§ã®ED25ã«çžåœïŒãæäžãããšã
ããŒã¿ãããè©Šéšã«ãããŠã¯å šã倱æãæ¹èµ·
ããªãã€ãã  ææ»ææ§äœçš éé¢ããŠã¹ã®æ»ææ§ éã®ããŠã¹ãïŒãïŒé±éã«ãŽã®äžã«éé¢ã
ãŠãããåçš®ã®ããŠã¹ã該ã«ãŽã«å ¥ãããšã
該éã®ããŠã¹ã¯åŸããå ¥ããããããŠã¹ãèª
çºçã«æ»æããã ããŠã¹ïŒè€æ°ïŒããèªçºçãªæ»ææ§ã瀺ã
ããã«ãªãæééé¢ãããæ»ææ§ãäžããã
ãããŠã¹äžå¹ãšéåžžã®éæ»ææ§ããŠã¹äžå¹ãš
ãåãå Žæã«å ¥ãã30åéã«è¡ãªãããæ»æ
æ§ããŠã¹ã®æ»ææ°ãèšé²ããã å矀ïŒbatchïŒã¯ïŒå¯Ÿã®ããŠã¹ããæãã 次ãã§å矀ã®æ»ææ§ããŠã¹ã«è©Šéšãã¹ãå
åç©ãæäžãããæäžéã¯ãå矀æ¯ã«å¢å ã
ããŠããã æäžããŠ30ååŸã察ãåã³åãå Žæã«å ¥
ããïŒåéã«è¡ãªãããæ»æã®æ°ãèšé²ã
ãã 次ãã§ED50å³ã¡ãæäžåã®æ»ææ°ã50ïŒ
以äžã«æžå°ãããæäžéãèšç®ãããååç©
ã®å ŽåED50ã¯142mg/Kgã§ãã€ãã åäžè©Šéšæ¡ä»¶äžã§ããžã¢ãŒãã ã®ïŒmg/Kg
以äžã®æäžéã§ã¯äœãã®çµæãåŸãããªãã€
ããïŒmg/Kgã®æäžéã§ã¯ã匷åãªé®éäœçš
ã瀺ããæ»ææ°æžå°çã¯38ïŒ ã§ãã€ããã¡ã
ããã¡ãŒãã®å ŽåãED50ã¯170mg/Kgã§ãã€
ãã ããŠã¹ãéé¢ããããšã«ããèªçºãããæ»
ææ§ã¯ã極ããŠæ£ç¢ºãªè¬çè©Šéšã§ããã ããªãŒãã¬ãŒãè©Šéšåã³é»æéäºè©Šéšã®
倫ã ã«ãããäžå®åã³æ»ææ§ã¯æ¡ä»¶åå¿ã§ã
ãã®ã«å¯Ÿããéé¢ããŠã¹ã®æ»ææ§ã¯ç²åŸæ§ã®
æ§è³ªã§ãããåäºè ã®å Žåãè¬å€ã¯ç¹å®ã®è¡
åã«ç¹ç°çã«äœçšããŠããããç¥ããªããã
æã¯ç¹ç°çã«ã§ã¯ãªãæ¡ä»¶ä»ãã®å åã®äœçš
ãå€æŽããŠäœçšããŠããã®ããç¥ããªãã ããããªããåŸè ã®å Žåã«ã¯ãè¬å€ã¯è¡å
ã«ç¹ç°çã«åã¯é®éäœçšãéããŠäœçšããŠã
ããšèããããã éé¢ããŠã¹ã®è©Šéšã«æŒããŠããžã¢ãŒãã ã¯
ããªãŒãã¬ãŒãè©ŠéšäžŠã³ã«é»æéäºè©Šéšã®äž¡
è©Šéšã«ãããŠå¥œé©ãªçµæãåŸãããæäžéã§
ã¯äœãã®äœçšãã瀺ããªãã€ãã ã¡ãããã¡ãŒãã«ã€ããŠã¯ãéé¢ããŠã¹ã®
è©Šéšã«ãããŠå¥œé©ãªçµæãåŸãã®ã«170mg/Kg
ã®æäžéãå¿ èŠã§ãã€ãããã®æäžéã§ã¯ã
é®éäœçšãèãããããŒã¿ãããè©Šéšçµæã¯
75ïŒ ã瀺ããã ãããšã¯å¯Ÿç §çã«ãååç©ïŒ¡ã¯çµå£æäžã§
100mg/Kgã®æäžéããææ»ææ§äœçšãçºæ®ã
ããããããã®æäžéã§ã¯é®éäœçšã¯çç¡ã§
ããã åŸã€ãŠååç©ïŒ¡ã¯ãäœããã®é®éäœçšãé
ããŠã§ã¯ãªãè¡åã«å¯ŸããäœçšãéããŠç¹ç°
çã«ææ»ææ§äœçšãçºæ®ããã®ã§ããããã®
ç¹ã«ãããŠãååç©ïŒ¡ã¯äžèšæ¯èŒè¬å€ããã
èããåªããŠãããå³ã¡ååç©ïŒ¡ã¯ãæ»ææ§
ã«å¯Ÿãæå¹ã§ããæäžéã«ãããŠã¯ãåŸç å
ã¯é®éãèªçºããªãã®ã§ããã æçæ£äœçšã®æž¬å® ãã³ãã¬ã³ããã©ãŸãŒã«âèªçºæ§æ¥çºäœãžã®äœ
çš ãã®è©Šéšã¯ãããŠã¹ã«ã€ããŠè¡ãªãããã®ç®
çã¯ãæ¬çºæååç©ãäºé²çã«çµå£æäžããã
ãã«ããæ¬çºæååç©ãååšããªããã°100ïŒ
èŽåœçã§ãããšããã®äºã決ããããéæäžã
ãããã³ãã¬ã³ããã©ãŸãŒã«ã«ããæ¹èµ·ããã
ç²ãçºäœããããŠã¹ãä¿è·ããããšãã§ããã
åŠãã決å®ããããšã«ããã è©Šéšãã¹ãååç©ãæäžãããã®15ååŸãã³
ãã¬ã³ããã©ãŸãŒã«ã125mg/Kg泚å°ããããã®
泚å°ã®åŸïŒæéã®éã«æ»äº¡ããããŠã¹ã®æ°ãèš
é²ãããçµæããæ»äº¡ã«è³ããããä¿è·ããçŸ
åçã§è¡šãããäžè¡šã«ç€ºãã
ãå°ãããç¹ã«ããŒã¿ãããè©Šéšã«ããã倱
æçãæ¯èŒããå Žåã«ã¯ãããé¡èã§ããã
æŽã«ãããªãŒãã¬ãŒãè©Šéšã«ãããŠãååç©
ã«ã€ããŠã¯é®éäœçšãäœã瀺ãããšãªã奜
é©ãªçµæãåŸããããããã¯ãã¡ãããã¡ãŒ
ãåã³ãžã¢ãŒãã ã§ã¯åŸãããªãã€ãã ååç©ïŒ«ã亊ããžã¢ãŒãã åã³ã¡ãããã¡
ãŒãã«æ¯ãäœãé®éäœçšãæããŠããããšã
å€ã€ããå³ã¡ããŠã¹ã«300mg/KgïŒããªãŒãã¬
ãŒãè©Šéšã§ã®ED25ã«çžåœïŒãæäžãããšã
ããŒã¿ãããè©Šéšã«ãããŠã¯å šã倱æãæ¹èµ·
ããªãã€ãã  ææ»ææ§äœçš éé¢ããŠã¹ã®æ»ææ§ éã®ããŠã¹ãïŒãïŒé±éã«ãŽã®äžã«éé¢ã
ãŠãããåçš®ã®ããŠã¹ã該ã«ãŽã«å ¥ãããšã
該éã®ããŠã¹ã¯åŸããå ¥ããããããŠã¹ãèª
çºçã«æ»æããã ããŠã¹ïŒè€æ°ïŒããèªçºçãªæ»ææ§ã瀺ã
ããã«ãªãæééé¢ãããæ»ææ§ãäžããã
ãããŠã¹äžå¹ãšéåžžã®éæ»ææ§ããŠã¹äžå¹ãš
ãåãå Žæã«å ¥ãã30åéã«è¡ãªãããæ»æ
æ§ããŠã¹ã®æ»ææ°ãèšé²ããã å矀ïŒbatchïŒã¯ïŒå¯Ÿã®ããŠã¹ããæãã 次ãã§å矀ã®æ»ææ§ããŠã¹ã«è©Šéšãã¹ãå
åç©ãæäžãããæäžéã¯ãå矀æ¯ã«å¢å ã
ããŠããã æäžããŠ30ååŸã察ãåã³åãå Žæã«å ¥
ããïŒåéã«è¡ãªãããæ»æã®æ°ãèšé²ã
ãã 次ãã§ED50å³ã¡ãæäžåã®æ»ææ°ã50ïŒ
以äžã«æžå°ãããæäžéãèšç®ãããååç©
ã®å ŽåED50ã¯142mg/Kgã§ãã€ãã åäžè©Šéšæ¡ä»¶äžã§ããžã¢ãŒãã ã®ïŒmg/Kg
以äžã®æäžéã§ã¯äœãã®çµæãåŸãããªãã€
ããïŒmg/Kgã®æäžéã§ã¯ã匷åãªé®éäœçš
ã瀺ããæ»ææ°æžå°çã¯38ïŒ ã§ãã€ããã¡ã
ããã¡ãŒãã®å ŽåãED50ã¯170mg/Kgã§ãã€
ãã ããŠã¹ãéé¢ããããšã«ããèªçºãããæ»
ææ§ã¯ã極ããŠæ£ç¢ºãªè¬çè©Šéšã§ããã ããªãŒãã¬ãŒãè©Šéšåã³é»æéäºè©Šéšã®
倫ã ã«ãããäžå®åã³æ»ææ§ã¯æ¡ä»¶åå¿ã§ã
ãã®ã«å¯Ÿããéé¢ããŠã¹ã®æ»ææ§ã¯ç²åŸæ§ã®
æ§è³ªã§ãããåäºè ã®å Žåãè¬å€ã¯ç¹å®ã®è¡
åã«ç¹ç°çã«äœçšããŠããããç¥ããªããã
æã¯ç¹ç°çã«ã§ã¯ãªãæ¡ä»¶ä»ãã®å åã®äœçš
ãå€æŽããŠäœçšããŠããã®ããç¥ããªãã ããããªããåŸè ã®å Žåã«ã¯ãè¬å€ã¯è¡å
ã«ç¹ç°çã«åã¯é®éäœçšãéããŠäœçšããŠã
ããšèããããã éé¢ããŠã¹ã®è©Šéšã«æŒããŠããžã¢ãŒãã ã¯
ããªãŒãã¬ãŒãè©ŠéšäžŠã³ã«é»æéäºè©Šéšã®äž¡
è©Šéšã«ãããŠå¥œé©ãªçµæãåŸãããæäžéã§
ã¯äœãã®äœçšãã瀺ããªãã€ãã ã¡ãããã¡ãŒãã«ã€ããŠã¯ãéé¢ããŠã¹ã®
è©Šéšã«ãããŠå¥œé©ãªçµæãåŸãã®ã«170mg/Kg
ã®æäžéãå¿ èŠã§ãã€ãããã®æäžéã§ã¯ã
é®éäœçšãèãããããŒã¿ãããè©Šéšçµæã¯
75ïŒ ã瀺ããã ãããšã¯å¯Ÿç §çã«ãååç©ïŒ¡ã¯çµå£æäžã§
100mg/Kgã®æäžéããææ»ææ§äœçšãçºæ®ã
ããããããã®æäžéã§ã¯é®éäœçšã¯çç¡ã§
ããã åŸã€ãŠååç©ïŒ¡ã¯ãäœããã®é®éäœçšãé
ããŠã§ã¯ãªãè¡åã«å¯ŸããäœçšãéããŠç¹ç°
çã«ææ»ææ§äœçšãçºæ®ããã®ã§ããããã®
ç¹ã«ãããŠãååç©ïŒ¡ã¯äžèšæ¯èŒè¬å€ããã
èããåªããŠãããå³ã¡ååç©ïŒ¡ã¯ãæ»ææ§
ã«å¯Ÿãæå¹ã§ããæäžéã«ãããŠã¯ãåŸç å
ã¯é®éãèªçºããªãã®ã§ããã æçæ£äœçšã®æž¬å® ãã³ãã¬ã³ããã©ãŸãŒã«âèªçºæ§æ¥çºäœãžã®äœ
çš ãã®è©Šéšã¯ãããŠã¹ã«ã€ããŠè¡ãªãããã®ç®
çã¯ãæ¬çºæååç©ãäºé²çã«çµå£æäžããã
ãã«ããæ¬çºæååç©ãååšããªããã°100ïŒ
èŽåœçã§ãããšããã®äºã決ããããéæäžã
ãããã³ãã¬ã³ããã©ãŸãŒã«ã«ããæ¹èµ·ããã
ç²ãçºäœããããŠã¹ãä¿è·ããããšãã§ããã
åŠãã決å®ããããšã«ããã è©Šéšãã¹ãååç©ãæäžãããã®15ååŸãã³
ãã¬ã³ããã©ãŸãŒã«ã125mg/Kg泚å°ããããã®
泚å°ã®åŸïŒæéã®éã«æ»äº¡ããããŠã¹ã®æ°ãèš
é²ãããçµæããæ»äº¡ã«è³ããããä¿è·ããçŸ
åçã§è¡šãããäžè¡šã«ç€ºãã
ãè¡šã
ãã®çµæãããæ¬çºæååç©ã¯ãäžè¬ã«åŒ±ã
æçæ£äœçšãæããŠããããšãããããïŒãã
ãååç©ïŒ£åã³ïŒ€ã¯åŒ·ãäœçšã瀺ããäŸå€ã§ã
ããïŒ ã³ãªããªãã€ãã¯ïŒcholinolyticïŒã®äœçšã®
æž¬å® ãã¬ã¢ãªã³ã«å¯Ÿããäœçš ãã®è©Šéšã¯ããšãã¬ããïŒEVERETTïŒã«
ããNature.1956ã177â238ã«èšèŒãããŠã
ãã ãã¬ã¢ãªã³ãããŠã¹ã«æ³šå°ãããšãæ«æ¢¢ã³ãª
ã³äœåæ§äœçšå³ã¡èœæ¶ïŒweepingïŒãéæµæ¶ã
é®éåã³äžç¢äžŠã³ã«äžæ¢ã³ãªã³äœåæ§äœçšå³ã¡
æ¯é¡«åã³ç¡åçãæ¹èµ·ãããã 10å¹ã®ããŠã¹ããæã矀ã«è©Šéšãã¹ãæ¬çºæ
ååç©ãçµå£æäžãã30ååŸãã¬ã¢ãªã³100mg/
Kgãè ¹è å æäžããã æ¯ãããã¬ã¢ãªã³ã®æäžéã§ã¯ãå¯Ÿç §ããŠã¹
ã¯100ïŒ äžæ¯ãèµ·ãããŠããããã¬ã¢ãªã³âèª
çºæ§äžæ¯ã®çš®ã ã®åŸ®åã瀺ãå矀ã®ããŠã¹ã®å²
åãèšé²ããã æ¯é¡«ã«ã€ãä¿è·ãããããŠã¹ã®æ°ã®çŸåçã
äžè¡šã«ç€ºãã
æçæ£äœçšãæããŠããããšãããããïŒãã
ãååç©ïŒ£åã³ïŒ€ã¯åŒ·ãäœçšã瀺ããäŸå€ã§ã
ããïŒ ã³ãªããªãã€ãã¯ïŒcholinolyticïŒã®äœçšã®
æž¬å® ãã¬ã¢ãªã³ã«å¯Ÿããäœçš ãã®è©Šéšã¯ããšãã¬ããïŒEVERETTïŒã«
ããNature.1956ã177â238ã«èšèŒãããŠã
ãã ãã¬ã¢ãªã³ãããŠã¹ã«æ³šå°ãããšãæ«æ¢¢ã³ãª
ã³äœåæ§äœçšå³ã¡èœæ¶ïŒweepingïŒãéæµæ¶ã
é®éåã³äžç¢äžŠã³ã«äžæ¢ã³ãªã³äœåæ§äœçšå³ã¡
æ¯é¡«åã³ç¡åçãæ¹èµ·ãããã 10å¹ã®ããŠã¹ããæã矀ã«è©Šéšãã¹ãæ¬çºæ
ååç©ãçµå£æäžãã30ååŸãã¬ã¢ãªã³100mg/
Kgãè ¹è å æäžããã æ¯ãããã¬ã¢ãªã³ã®æäžéã§ã¯ãå¯Ÿç §ããŠã¹
ã¯100ïŒ äžæ¯ãèµ·ãããŠããããã¬ã¢ãªã³âèª
çºæ§äžæ¯ã®çš®ã ã®åŸ®åã瀺ãå矀ã®ããŠã¹ã®å²
åãèšé²ããã æ¯é¡«ã«ã€ãä¿è·ãããããŠã¹ã®æ°ã®çŸåçã
äžè¡šã«ç€ºãã
ãè¡šã
æŽã«ååç©ïŒ¡ã¯ã100ã300ã400åã³500mg/
Kgçµå£æäžããå Žåã§ãããã¬ã¢ãªã³ã«ããæ¹
èµ·ãããäžæ¢è¥ããã¯æ«æ¢¢ã³ãªã³äœåæ§äœçšã
ãããŠã¹ãå šãä¿è·ããªãã€ãã åŸã€ãŠãæ¬çºæååç©ã¯ãäžèšè©Šéšã«ãã
ãŠãã³ãªã³æå¶æ§äœçšãå šãæããªãã æ¥æ§æ¯æ§ã®æž¬å® æ¥æ§æ¯æ§ãã¹ã€ã¹E.O.P.SããŠã¹ã«ã€ãçµå£
æäžããŠæž¬å®ãããçšããæ¹æ³ã¯ããªãããã€
ãŒã«ãïŒLITCHFIELDïŒãšãŠã€ã«ã³ã¯ã¹ã³
ïŒWILCOXONïŒã«ããJ.Pharmacol.Exp.Ther.
1946ã96ã99ã«èšèŒã®ãã®ã§ããã ååç©ïŒ¡ã®LD50ã¯ããŠã¹ã®å Žåãã©ããã®
å Žåã300mg/Kg以äžã§ãã€ãã ïŒæ¥é芳å¯ããçµæã3000mg/Kgã®æäžéã§
ããããŠã¹ã®å ŽåãããïŒïŒ ãã©ããã®å Žå10
ïŒ ã®æ»äº¡ã確èªãããã®ã¿ã§ãã€ãã ããŠã¹ã«ãããä»ã®æ¬çºæååç©ã®LD0ã®å³
ã¡èŠ³å¯äžã«ããŠã¹ãæ»ã«è³ããããªãæ倧æäž
éã¯ãäžè¬çã«çµå£æäžã§600mg/Kg以äžã§ãã€
ãã æ¬çºæååç©ãæ²»ççšã«çšããå Žåã¯ãéåžž
è¬ççåã¯ç£å»åŠççµæç©ã®åœ¢æ ã§æäžããã
ãšãã§ãã該çµæç©ã¯ç®çãšããæäžæ§åŒã«é©
ããæäžåäœãšããããšãã§ããã該çµæç©
ã¯ãæå¹æåãšããŠæ¬çºæååç©ã®å°ãªããšã
ïŒçš®ãè¬çæ äœè¥ããã¯è³Šåœ¢å€ãšå ±ã«å«æã
ãã 該çµæç©ãçµå£æäžããå Žåã«ã¯ãäŸãã°è¢«
èŠè¥ããã¯ç¡è¢«èŠé å€ã硬âè¥ããã¯è»âãŒã©
ãã³ã«ãã»ã«ãæžæ¿æ¶²ãã·ãããçã®åœ¢æ ãšã
ãããšãã§ãããåçŽè žå æäžçšã«ã¯åè¬ãšã
ãããšãã§ããã 該çµæç©ã¯ãäžæäžåäœåœããçµå£æäžåã¯
çŽè žå æäžçšãšããŠãæå¹æåã50ã500mg奜
ãŸããã¯200ã250mgå«æããã æ¬çºæã®çµæç©ã¯ãäžè¬åŒïŒïŒã®ååç©ã®
å°ãªããšãïŒçš®ãšé©åœãªæ äœè¥ããã¯è³Šåœ¢å€ãš
ããã€ãŠèª¿è£œããããšãã§ããã 奜ãŸããæ äœè¥ããã¯è³Šåœ¢å€ãšããŠã¯ãèžç
æ°Žãã¿ã«ã¯ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã³ã
ã€ãã«ã·ãªã«ãä¹³ç³ããµãã«ããŒã¹ãã«ã«ãã
ã·ã¡ãã«ã»ã«ããŒã¹ãå°éºŠã¹ã¿ãŒãåã³ã³ãŒã³
ã¹ã¿ãŒããã«ãªãªã³ãã¬ãã©ã€ãïŒleviliteïŒã
ã«ã«ãªãã¿ãŒçãäŸç€ºã§ããã 以äžãæ¬çºæã§äœ¿çšããååç©ã®è£œé äŸåã³æ¬
çºæè¬ççµæç©ã®å®æœäŸãèšèŒããã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ïŒâå°¿çŽ å³ã¡ããªâïœâãããã«ã¡ãã«å°¿çŽ
ã®è£œé åçž®åšã枩床èšåã³ãã€ãããŠãŒããåä»ãã
ïŒã€å£ãã©ã¹ã³äžã§ã也ç¥ãžãªããµã³300mläžã«
ã¢ã³ã¢ãã¢ãããã«ããããã®ã¢ã³ã¢ãã¢é£œå溶
液ã60âã«ä¿æãããã®äžã«åèžçããïŒã»ïŒâ
ãžâïœâãããã«âïœâããã«ã€ãœã·ã¢ããŒã17
ïœïŒ0.092ã¢ã«ïŒã90åãèŠããŠå ãããæ·»å çµ
äºåŸã溶液ãïŒæéå ç±éæµãã次ãã§ãžãªããµ
ã³ãæžå§äžçå»ãããããããŠåŸãããç¡è²çµæ¶
ãã¢ã»ããããªã«60mlããåçµæ¶ãããã ããããŠç¡è²çµæ¶ã®ïŒâïŒïŒã»ïŒâãžâïœâã
ããã«âïœâããã«ïŒâå°¿çŽ 14ïœãåŸããèç¹123
âãåç76ïŒ ã å°ãã¢ã³ã¢ãã¢ã®ãžãªããµã³æº¶æ¶²ã«ä»£ããŠãæ¿
ã¢ã³ã¢ãã¢æº¶æ¶²ïŒïœïŒ0.92ïŒãçšããããšãã§ã
ãã é©åœãªåºçºåæãçšããäžèšãšåæ§ã«ããŠäžèš
ååç©ãåŸãã
Kgçµå£æäžããå Žåã§ãããã¬ã¢ãªã³ã«ããæ¹
èµ·ãããäžæ¢è¥ããã¯æ«æ¢¢ã³ãªã³äœåæ§äœçšã
ãããŠã¹ãå šãä¿è·ããªãã€ãã åŸã€ãŠãæ¬çºæååç©ã¯ãäžèšè©Šéšã«ãã
ãŠãã³ãªã³æå¶æ§äœçšãå šãæããªãã æ¥æ§æ¯æ§ã®æž¬å® æ¥æ§æ¯æ§ãã¹ã€ã¹E.O.P.SããŠã¹ã«ã€ãçµå£
æäžããŠæž¬å®ãããçšããæ¹æ³ã¯ããªãããã€
ãŒã«ãïŒLITCHFIELDïŒãšãŠã€ã«ã³ã¯ã¹ã³
ïŒWILCOXONïŒã«ããJ.Pharmacol.Exp.Ther.
1946ã96ã99ã«èšèŒã®ãã®ã§ããã ååç©ïŒ¡ã®LD50ã¯ããŠã¹ã®å Žåãã©ããã®
å Žåã300mg/Kg以äžã§ãã€ãã ïŒæ¥é芳å¯ããçµæã3000mg/Kgã®æäžéã§
ããããŠã¹ã®å ŽåãããïŒïŒ ãã©ããã®å Žå10
ïŒ ã®æ»äº¡ã確èªãããã®ã¿ã§ãã€ãã ããŠã¹ã«ãããä»ã®æ¬çºæååç©ã®LD0ã®å³
ã¡èŠ³å¯äžã«ããŠã¹ãæ»ã«è³ããããªãæ倧æäž
éã¯ãäžè¬çã«çµå£æäžã§600mg/Kg以äžã§ãã€
ãã æ¬çºæååç©ãæ²»ççšã«çšããå Žåã¯ãéåžž
è¬ççåã¯ç£å»åŠççµæç©ã®åœ¢æ ã§æäžããã
ãšãã§ãã該çµæç©ã¯ç®çãšããæäžæ§åŒã«é©
ããæäžåäœãšããããšãã§ããã該çµæç©
ã¯ãæå¹æåãšããŠæ¬çºæååç©ã®å°ãªããšã
ïŒçš®ãè¬çæ äœè¥ããã¯è³Šåœ¢å€ãšå ±ã«å«æã
ãã 該çµæç©ãçµå£æäžããå Žåã«ã¯ãäŸãã°è¢«
èŠè¥ããã¯ç¡è¢«èŠé å€ã硬âè¥ããã¯è»âãŒã©
ãã³ã«ãã»ã«ãæžæ¿æ¶²ãã·ãããçã®åœ¢æ ãšã
ãããšãã§ãããåçŽè žå æäžçšã«ã¯åè¬ãšã
ãããšãã§ããã 該çµæç©ã¯ãäžæäžåäœåœããçµå£æäžåã¯
çŽè žå æäžçšãšããŠãæå¹æåã50ã500mg奜
ãŸããã¯200ã250mgå«æããã æ¬çºæã®çµæç©ã¯ãäžè¬åŒïŒïŒã®ååç©ã®
å°ãªããšãïŒçš®ãšé©åœãªæ äœè¥ããã¯è³Šåœ¢å€ãš
ããã€ãŠèª¿è£œããããšãã§ããã 奜ãŸããæ äœè¥ããã¯è³Šåœ¢å€ãšããŠã¯ãèžç
æ°Žãã¿ã«ã¯ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã³ã
ã€ãã«ã·ãªã«ãä¹³ç³ããµãã«ããŒã¹ãã«ã«ãã
ã·ã¡ãã«ã»ã«ããŒã¹ãå°éºŠã¹ã¿ãŒãåã³ã³ãŒã³
ã¹ã¿ãŒããã«ãªãªã³ãã¬ãã©ã€ãïŒleviliteïŒã
ã«ã«ãªãã¿ãŒçãäŸç€ºã§ããã 以äžãæ¬çºæã§äœ¿çšããååç©ã®è£œé äŸåã³æ¬
çºæè¬ççµæç©ã®å®æœäŸãèšèŒããã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ïŒâå°¿çŽ å³ã¡ããªâïœâãããã«ã¡ãã«å°¿çŽ
ã®è£œé åçž®åšã枩床èšåã³ãã€ãããŠãŒããåä»ãã
ïŒã€å£ãã©ã¹ã³äžã§ã也ç¥ãžãªããµã³300mläžã«
ã¢ã³ã¢ãã¢ãããã«ããããã®ã¢ã³ã¢ãã¢é£œå溶
液ã60âã«ä¿æãããã®äžã«åèžçããïŒã»ïŒâ
ãžâïœâãããã«âïœâããã«ã€ãœã·ã¢ããŒã17
ïœïŒ0.092ã¢ã«ïŒã90åãèŠããŠå ãããæ·»å çµ
äºåŸã溶液ãïŒæéå ç±éæµãã次ãã§ãžãªããµ
ã³ãæžå§äžçå»ãããããããŠåŸãããç¡è²çµæ¶
ãã¢ã»ããããªã«60mlããåçµæ¶ãããã ããããŠç¡è²çµæ¶ã®ïŒâïŒïŒã»ïŒâãžâïœâã
ããã«âïœâããã«ïŒâå°¿çŽ 14ïœãåŸããèç¹123
âãåç76ïŒ ã å°ãã¢ã³ã¢ãã¢ã®ãžãªããµã³æº¶æ¶²ã«ä»£ããŠãæ¿
ã¢ã³ã¢ãã¢æº¶æ¶²ïŒïœïŒ0.92ïŒãçšããããšãã§ã
ãã é©åœãªåºçºåæãçšããäžèšãšåæ§ã«ããŠäžèš
ååç©ãåŸãã
ãè¡šã
äžèšååç©ã¯ãã¢ã»ããããªã«ããåçµæ¶ãã
ãããšã«ãã粟補ããããã ãïŒâïŒïŒã»ïŒâãž
ãšãã«âïœâãããã«ïŒå°¿çŽ ã¯ã¢ã»ããããªã«ïŒ
æ°ŽïŒ80ïŒ20ïŒæ··å溶åªããåçµæ¶ãããã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâãžãšãã«âïŒâããããã«ïŒâå°¿
çŽ ã®è£œé æ¹æäžãïŒâïŒïŒã»ïŒâãžãšãã«âïŒâããã
ãã«ïŒâã¢ãã³11.1ïœïŒ0.1ã¢ã«ïŒããããå°¿çŽ 10.5
ïœåã³èžçæ°Ž40mlãïŒæé50âã§å ç±ããããã
ããŠåŸãããäžæº¶æ§çæç©ãåããæ°ŽæŽãã也
ç¥ããã é ¢é žãšãã«ããåçµæ¶ãããŠãïŒâïŒïŒã»ïŒâ
ãžãšãã«âïŒâããããã«ïŒâå°¿çŽ 6.6ïœãç¡è²çµ
æ¶ã®åœ¢æ ã§åŸããèç¹108âãåç40ïŒ ã é©åœãªåºçºåæãçšããäžèšãšåæ§ã«ããŠäžèš
ååç©ãåŸãã
ãããšã«ãã粟補ããããã ãïŒâïŒïŒã»ïŒâãž
ãšãã«âïœâãããã«ïŒå°¿çŽ ã¯ã¢ã»ããããªã«ïŒ
æ°ŽïŒ80ïŒ20ïŒæ··å溶åªããåçµæ¶ãããã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâãžãšãã«âïŒâããããã«ïŒâå°¿
çŽ ã®è£œé æ¹æäžãïŒâïŒïŒã»ïŒâãžãšãã«âïŒâããã
ãã«ïŒâã¢ãã³11.1ïœïŒ0.1ã¢ã«ïŒããããå°¿çŽ 10.5
ïœåã³èžçæ°Ž40mlãïŒæé50âã§å ç±ããããã
ããŠåŸãããäžæº¶æ§çæç©ãåããæ°ŽæŽãã也
ç¥ããã é ¢é žãšãã«ããåçµæ¶ãããŠãïŒâïŒïŒã»ïŒâ
ãžãšãã«âïŒâããããã«ïŒâå°¿çŽ 6.6ïœãç¡è²çµ
æ¶ã®åœ¢æ ã§åŸããèç¹108âãåç40ïŒ ã é©åœãªåºçºåæãçšããäžèšãšåæ§ã«ããŠäžèš
ååç©ãåŸãã
ãè¡šã
å°¿çŽ
ãããååç©ã¯é ¢é žãšãã«ããåçµæ¶ãããã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ïŒâïŒâïŒïŒâããããã«ïŒâå°¿çŽ ã®è£œé ããã¿ã³20mlã«æº¶è§£ãããïŒã»ïŒâãžâïœâã
ããã«âïœâããã«ã€ãœã·ã¢ããŒã3.66ïœïŒ0.02
ã¢ã«ïŒäžã«ãã¢ãªã«ã¢ãã³1.14ïœïŒ0.02ã¢ã«ïŒã
å ãããæ··åç©ã60âã«ãŠïŒæéå ç±æ¹æããã
次ãã§ããã¿ã³ãç空äžã«çå»ããåŸãããçæ
ç©ãæ°Ž30ïŒ ãå«æããã¢ã»ããããªã«ããåçµæ¶
ãããã ããããŠïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœ
âããã«ïŒâïŒâïŒïŒâããããã«ïŒâå°¿çŽ 3.6ïœã
ç¡è²çµæ¶ã®åœ¢æ ã§åŸããèç¹66âãåç75ïŒ ã é©åœãªåºçºåæãçšããäžèšãšåæ§ã«ããŠäžèš
ååç©ãåŸãã
ãããååç©ã¯é ¢é žãšãã«ããåçµæ¶ãããã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ïŒâïŒâïŒïŒâããããã«ïŒâå°¿çŽ ã®è£œé ããã¿ã³20mlã«æº¶è§£ãããïŒã»ïŒâãžâïœâã
ããã«âïœâããã«ã€ãœã·ã¢ããŒã3.66ïœïŒ0.02
ã¢ã«ïŒäžã«ãã¢ãªã«ã¢ãã³1.14ïœïŒ0.02ã¢ã«ïŒã
å ãããæ··åç©ã60âã«ãŠïŒæéå ç±æ¹æããã
次ãã§ããã¿ã³ãç空äžã«çå»ããåŸãããçæ
ç©ãæ°Ž30ïŒ ãå«æããã¢ã»ããããªã«ããåçµæ¶
ãããã ããããŠïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœ
âããã«ïŒâïŒâïŒïŒâããããã«ïŒâå°¿çŽ 3.6ïœã
ç¡è²çµæ¶ã®åœ¢æ ã§åŸããèç¹66âãåç75ïŒ ã é©åœãªåºçºåæãçšããäžèšãšåæ§ã«ããŠäžèš
ååç©ãåŸãã
ãè¡šã
補é äŸ ïŒ
ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ïŒâïŒâã¡ãã«âå°¿çŽ ã®è£œé ïŒã»ïŒâãžâïœâãããã«âïœâããã«ã¢ãã³
7.9ïœïŒ0.05ã¢ã«ïŒã®ãšãŒãã«æº¶æ¶²ã«ãã¡ãã«ã€
ãœã·ã¢ããŒã3.42ïœïŒ0.06ã¢ã«ïŒããšãŒãã«15ml
ã«æº¶è§£ããã溶液ãé€ã ã«å ãããæ··åç©ã宀枩
äž10åéæ¹æããæ¿çž®ã也åºãããã ãããã€ãœãããã«ãšãŒãã«ããåçµæ¶ãã
ãŠãç¡è²çµæ¶ã®ïŒâïŒïŒã»ïŒâãžâïœâãããã«
âïœâããã«ïŒâïŒâã¡ãã«âå°¿çŽ 7.1ïœãåŸãã
èç¹120âãåç67ïŒ ã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâïœâãããã«âïœâããã«ïŒâ
ïŒã»ïŒâãžã¡ãã«âå°¿çŽ ã®è£œé æ¹æäžãïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ã€ãœã·ã¢ããŒã3.66ïœïŒ0.02ã¢ã«ïŒäžã«ããžã¡
ãã«ã¢ãã³ã®40ïŒ æ°Žæº¶æ¶²2.5mlãé€ã ã«å ããã
ç¡è²çµæ¶ãæ²æ®¿ãããã¢ãã³ã®æ·»å çµäºåŸãèžç
æ°Ž10mlãå ããæ··åç©ãïŒæéæ¹æãããåŸãã
ãçµæ¶ãåããããã¿ã³ïŒã·ã¯ããããµã³20ïŒ
å«æïŒããåçµæ¶ãããã ããããŠãïŒâïŒïŒã»ïŒâãžâïœâãããã«â
ïœâããã«ïŒâïŒã»ïŒâãžã¡ãã«âå°¿çŽ 3.6ïœãç¡
è²çµæ¶ã®åœ¢æ ã§åŸããèç¹88âãåç80ïŒ ã å®æœäŸ ïŒ å ¬ç¥ã®è¬å€è£œé æ³ã«åŸã€ãŠãäžèšæåãå«æã
ã硬âãŒã©ãã³ã«ãã»ã«ã補é ããã
ã«ïŒâïŒâã¡ãã«âå°¿çŽ ã®è£œé ïŒã»ïŒâãžâïœâãããã«âïœâããã«ã¢ãã³
7.9ïœïŒ0.05ã¢ã«ïŒã®ãšãŒãã«æº¶æ¶²ã«ãã¡ãã«ã€
ãœã·ã¢ããŒã3.42ïœïŒ0.06ã¢ã«ïŒããšãŒãã«15ml
ã«æº¶è§£ããã溶液ãé€ã ã«å ãããæ··åç©ã宀枩
äž10åéæ¹æããæ¿çž®ã也åºãããã ãããã€ãœãããã«ãšãŒãã«ããåçµæ¶ãã
ãŠãç¡è²çµæ¶ã®ïŒâïŒïŒã»ïŒâãžâïœâãããã«
âïœâããã«ïŒâïŒâã¡ãã«âå°¿çŽ 7.1ïœãåŸãã
èç¹120âãåç67ïŒ ã 補é äŸ ïŒ ïŒâïŒïŒã»ïŒâïœâãããã«âïœâããã«ïŒâ
ïŒã»ïŒâãžã¡ãã«âå°¿çŽ ã®è£œé æ¹æäžãïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ã€ãœã·ã¢ããŒã3.66ïœïŒ0.02ã¢ã«ïŒäžã«ããžã¡
ãã«ã¢ãã³ã®40ïŒ æ°Žæº¶æ¶²2.5mlãé€ã ã«å ããã
ç¡è²çµæ¶ãæ²æ®¿ãããã¢ãã³ã®æ·»å çµäºåŸãèžç
æ°Ž10mlãå ããæ··åç©ãïŒæéæ¹æãããåŸãã
ãçµæ¶ãåããããã¿ã³ïŒã·ã¯ããããµã³20ïŒ
å«æïŒããåçµæ¶ãããã ããããŠãïŒâïŒïŒã»ïŒâãžâïœâãããã«â
ïœâããã«ïŒâïŒã»ïŒâãžã¡ãã«âå°¿çŽ 3.6ïœãç¡
è²çµæ¶ã®åœ¢æ ã§åŸããèç¹88âãåç80ïŒ ã å®æœäŸ ïŒ å ¬ç¥ã®è¬å€è£œé æ³ã«åŸã€ãŠãäžèšæåãå«æã
ã硬âãŒã©ãã³ã«ãã»ã«ã補é ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ãåŒäžR1ãR2åã³R3ã¯åäžåã¯çžç°ã€ãŠå€«ã ççŽ
æ°ïŒãïŒã®çŽéåã¯åæã®ã¢ã«ãã«åºåã¯ã¢ã«ã
ãã«åºåã¯ïŒâããããã«åºã瀺ããR4åã³R5
ã¯åäžåã¯çžç°ã€ãŠå€«ã æ°ŽçŽ åååã¯ççŽ æ°ïŒã
ïŒã®çŽéåã¯åæã®ã¢ã«ãã«åºãã¢ã«ã±ãã«åºå
ã¯ã¢ã«ããã«åºã瀺ããäœããR1ãR2åã³R3ã«
é¢ã (a) ãã®ãã¡å¯äžã€ã®åºã®ã¿ããã¡ãã«å°¿çŽ åºã«
é¢ããŠÎ±ãβäœã«äžé£œåçµåãæããã¢ã«ãã
ã«åºã瀺ãããã®å Žåä»ã®ïŒã€ã®åºã¯å€«ã ã¢ã«
ãã«åºã瀺ããã®ãšããæŽã« (b) ãããåºã®ççŽ æ°ã®ç·åã¯ãïŒæªæºãšãªããª
ããã®ãšãããã ã§è¡šããããå°¿çŽ èªå°äœã®å°ãªããšãïŒçš®ãæ
å¹æåãšãã人åã³åç©çšã®äžå®é€å»åã³ææ»
æå€ã ïŒ ïŒâïŒïŒã»ïŒâãžâïœâãããã«âïœâãã
ã«ïŒå°¿çŽ ãæå¹æåãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®äººåã³åç©çšã®äžå®é€å»åã³ææ»æå€ã
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7633213A FR2369837A1 (fr) | 1976-11-04 | 1976-11-04 | Derives actifs de l'uree, leur procede de preparation ainsi que les compositions therapeutiques les contenant |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5359625A JPS5359625A (en) | 1978-05-29 |
JPS6153324B2 true JPS6153324B2 (ja) | 1986-11-17 |
Family
ID=9179521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13296577A Granted JPS5359625A (en) | 1976-11-04 | 1977-11-04 | Urea derivatives* manufacturing process thereof and pharmacological and verterinary compositions containing it |
Country Status (10)
Country | Link |
---|---|
US (1) | US4223041A (ja) |
JP (1) | JPS5359625A (ja) |
BE (1) | BE860162A (ja) |
CH (1) | CH630608A5 (ja) |
DE (1) | DE2749520A1 (ja) |
ES (2) | ES463864A1 (ja) |
FR (1) | FR2369837A1 (ja) |
GB (1) | GB1548466A (ja) |
IT (1) | IT1087649B (ja) |
NL (1) | NL7711936A (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624958A (en) * | 1987-12-31 | 1997-04-29 | Isaacs; Charles E. | Disinfecting contact lenses |
US5434182A (en) * | 1987-12-31 | 1995-07-18 | Isaacs; Charles E. | Antibacterial fatty acid compositions |
US4880836A (en) * | 1988-03-11 | 1989-11-14 | Danek Elbaum | Antiviral amphiphilics |
US5451651A (en) * | 1993-12-17 | 1995-09-19 | Bausch & Lomb Incorporated | Urea and urethane monomers for contact lens materials |
FR2741066B1 (fr) * | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
US20110034565A1 (en) * | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US10124666B2 (en) | 2015-09-08 | 2018-11-13 | High Stone Technologies, LLC | Wheelchair drive boost |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2999110A (en) * | 1959-08-05 | 1961-09-05 | Olin Mathieson | 1-(substituted phenyl alkanoyl)-3-alkoxy ureas |
US3110728A (en) * | 1960-07-29 | 1963-11-12 | Dainippon Pharmaceutical Co | Nu-phenylacetyl-n'-acylureas |
US3852473A (en) * | 1973-01-31 | 1974-12-03 | Smith Kline French Lab | Method and composition for increasing feed intake of animals using tertiary alcohols |
US4026925A (en) * | 1974-05-20 | 1977-05-31 | Labaz | Active derivatives of methylamine, therapeutic compositions containing the same and processes for preparing the said derivatives and compositions |
-
1976
- 1976-11-04 FR FR7633213A patent/FR2369837A1/fr active Granted
-
1977
- 1977-10-25 US US05/844,618 patent/US4223041A/en not_active Expired - Lifetime
- 1977-10-26 IT IT28995/77A patent/IT1087649B/it active
- 1977-10-27 BE BE182101A patent/BE860162A/xx not_active IP Right Cessation
- 1977-10-28 GB GB45098/77A patent/GB1548466A/en not_active Expired
- 1977-10-31 NL NL7711936A patent/NL7711936A/xx not_active Application Discontinuation
- 1977-11-03 CH CH1341077A patent/CH630608A5/fr not_active IP Right Cessation
- 1977-11-04 DE DE19772749520 patent/DE2749520A1/de not_active Withdrawn
- 1977-11-04 ES ES463864A patent/ES463864A1/es not_active Expired
- 1977-11-04 JP JP13296577A patent/JPS5359625A/ja active Granted
-
1978
- 1978-08-01 ES ES472263A patent/ES472263A1/es not_active Expired
Also Published As
Publication number | Publication date |
---|---|
GB1548466A (en) | 1979-07-18 |
BE860162A (fr) | 1978-04-27 |
JPS5359625A (en) | 1978-05-29 |
FR2369837B1 (ja) | 1979-02-23 |
US4223041A (en) | 1980-09-16 |
FR2369837A1 (fr) | 1978-06-02 |
CH630608A5 (fr) | 1982-06-30 |
DE2749520A1 (de) | 1978-05-11 |
NL7711936A (nl) | 1978-05-08 |
ES472263A1 (es) | 1979-02-16 |
ES463864A1 (es) | 1979-01-01 |
IT1087649B (it) | 1985-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT736004E (pt) | (2,4-dissulfofenil)-n-terc-butil-nitrona seus sais e sua utilizacao como agentes farmaceuticos capturadores de radicais livres | |
JPS6153324B2 (ja) | ||
US4425336A (en) | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes | |
KR20010013230A (ko) | í-ë¶ì 맥 ì¡°ì±ë¬Œ ë° ì¹ë£ ë°©ë² | |
CH544066A (de) | Verfahren zur Herstellung von Fluorenverbindungen | |
EP3968990A1 (en) | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2 | |
JPS62298566A (ja) | ïŒïŒïŒâã«ã«ããã³ã¢ã«ãã«ã¢ãã | |
US3097136A (en) | Process for producing a depressant-like effect on the central nervous system | |
US3560619A (en) | Aminoquinazolines and quinazolones in treatment of coccidiosis | |
EP0187009B1 (en) | Compounds and compositions having anti-inflammatory and analgesic activity | |
DE2348577C2 (de) | 1-Amino-4-phenyl-1,2,3,4-tetrahydronaphthaline, deren pharmakologisch vertrÀglichen Salze und diese enthaltende pharmazeutische Zubereitungen | |
US4188398A (en) | Method for treating epilepsy | |
DE2213028B2 (de) | Dl-3-formylaminothiacyclopentan-2- on-, verfahren zu dessen herstellung und dl-3-formylamino-thiacyclopentan-2-on und andere acylderivate enthaltende pharmazeutische zusammensetzungen | |
KR100457113B1 (ko) | ìžëŒë§ìŽëë¥ ëë ê·ž ì ë첎ì ë€ìŽë©ížì€íê³ ì ì ì íšì±ë¶ìŒë¡ í¬íšíë ë°©ì¬ì 믌ê°ë ìŠì§ì | |
US3218232A (en) | Method for relieving depression and composition therefor | |
US4297373A (en) | Method of suppressing cardiac arrhythmias | |
DE2227842C3 (de) | Diphenylcyclopentane und diese enthaltende Arzneimittel | |
HU213112B (en) | Process for preparing antidepressive pharmaceutical preparations | |
NL7908286A (nl) | Preparaat voor het behandelen van fysiologische aandoe- ningen bij mammaliaspecies, die worden gekenmerkt door aberrante hoogfrequentieontlading van zenuwvezels. | |
US4714707A (en) | Aryl substituted heterocycles for treating gastrointestinal motility dysfunction | |
FI66597C (fi) | Foerfarande foer framstaellning av en antiarrytmisk 4-hydroxi-3-metoxi-n-(2-(2-(1-metyl-2-piperidinyl)-etyl)fenyl)bensamidoch farmaceutisk godtagbara syraadditionssalter daerav | |
JP3681770B2 (ja) | è幎æ§çŽåçåã¯ã¢ã«ããã€ããŒç æ²»çå€ | |
JPS6326732B2 (ja) | ||
DE1211645B (de) | Verfahren zur Herstellung von 4-Hydroxytryptaminphosphorsaeureestern | |
US3304229A (en) | Composition containing lincomycin salt |